Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation by Charlton, Michael R. et al.
SPECIAL ARTICLE
Report of the First International Liver
Transplantation Society Expert Panel Consensus
Conference on Renal Insufficiency in Liver
Transplantation
Michael R. Charlton,1 William J. Wall,2 Akinlolu O. Ojo,3 Pere Ginès,4 Stephen Textor,1
Fuad S. Shihab,5 Paul Marotta,6 Marcelo Cantarovich,7 James D. Eason,8 Russell H. Wiesner,1
Michael A. Ramsay,9 Juan C. Garcia-Valdecasas,10 James M. Neuberger,11 Sandy Feng,12
Connie L. Davis,13 Thomas A. Gonwa,14 and the International Liver Transplantation Society Expert
Panel
1Mayo Clinic, Rochester MN; 2Department of General Surgery, London Health Science Center, London,
Ontario, Canada; 3Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI;
4Liver Unit, Hospital Clinic, University of Barcelona School of Medicine, Barcelona, Spain; 5Department of
Nephrology, University of Utah School of Medicine, Salt Lake City, UT; 6Medical School, University of
Western Ontario, London, Ontario, Canada; 7Department of Medicine, McGill University Health Center,
Montreal, Quebec, Canada; 8Transplant Institute, University of Tennessee, Memphis, TN; 9Baylor University
Medical Center, Dallas, TX; 10Hospital Clinic I Provincial, Barcelona, Spain; 11Queen Elizabeth Hospital,
Birmingham, England; 12Department of Transplant Surgery, University of California San Francisco Medical
Center, San Francisco, CA; 13Department of Medicine, University of Washington Medical Center, Seattle,
WA; and 14Mayo Clinic, Jacksonville, FL
Received March 30, 2009; accepted June 25, 2009.
This supplement is supported by an unrestricted educational grant from Bristol-Myers Squibb.
LIVER TRANSPLANTATION 15:S1-S34, 2009
S1Liver Transplantation, Vol 15, No 11, Suppl 2 (Month), 2009: pp S1-S34
PREVALENCE, IMPACT, AND ETIOLOGY OF RENAL INSUFFICIENCY IN LIVER TRANSPLANTATION
Scope of the Problem and Impact on Outcomes
Akinlolu O. Ojo
Both acute kidney injury (AKI) and chronic kidney dis-
ease (CKD) are highly prevalent in liver transplantation,
affecting 25% to 50% and 30% to 90% of recipients,
respectively. The risk of end-stage renal disease (ESRD)
requiring renal replacement therapy (RRT) ranges from
2% to 5% per year in the posttransplant period. Periop-
erative AKI with the need for RRT is associated with a 3-
to 4-fold increase in the 30-day posttransplant mortal-
ity rate, and the 1-year survival rate in liver transplant
recipients requiring perioperative dialysis support
could be as low as 47% versus 92% for those recipients
not requiring postoperative dialytic support. The etiol-
ogy of AKI and CKD in liver transplant recipients is
multifactorial, with pretransplant kidney disease and
posttransplant immunosuppressant nephrotoxicity
playing major etiogenic and aggravating roles. Preven-
tative clinical management is frustrated by the gross
imprecision or impracticality of the clinical methods
available to diagnose kidney disease before and after
liver transplantation. Borrowed therapeutic strategies
such as calcineurin inhibitor minimization, substitu-
tion, and withdrawal are commonly employed to miti-
gate the progression of posttransplant kidney disease,
but the evidence is scanty that these approaches pro-
long renal survival or mitigate the severity of CKD. The
simultaneous implantation of a deceased donor kidney
along with a liver allograft in patients with advanced
renal insufficiency at the time of liver transplantation
has gained substantial currency in a small number of
liver transplant programs, but the criteria to determine
the suitability of recipients of simultaneous liver-kid-
ney transplantation are not standardized or rigorously
formulated, and the survival benefits of the latter ap-
proach with respect to appropriate controls and alter-
native strategies have not been determined. Treatment
of ESRD after liver transplantation with kidney trans-
plantation appears to be overwhelmingly superior to
long-term maintenance dialysis therapy with respect to
recipient survival (10-year survival of 71% versus 20%,
P  0.005). Mechanistic and long-term clinical outcome
studies specific to liver transplant populations are
needed to better understand the etiology and mecha-
nisms of the progression of kidney dysfunction. Such
studies are necessary steps toward defining appropri-
ate therapeutic targets and defining preventative strat-
egies
RISK FACTORS
The calcineurin inhibitors tacrolimus and cyclosporine
remain the cornerstone of maintenance immunosup-
pression in liver transplantation. Nephrotoxicity due to
calcineurin inhibitors mediates several known clinical
syndromes, including AKI and CKD. These well-recog-
nized clinical syndromes and the nearly uniform find-
ings of renal injury in patients exposed to long-term
calcineurin inhibitors provide a strong basis for the
presumption that calcineurin inhibition is the domi-
nant cause of kidney dysfunction in liver transplant
recipients (Fig. 1). Other risk factors known to predis-
pose to renal insufficiency in liver transplant recipients
include elevated pretransplant serum creatinine, pre-
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transplant and posttransplant diabetes mellitus, and
hypertension.1-3 Hepatitis C infection is associated
with multiple glomerular diseases, including membra-
nous glomerulonephritis, mixed essential cryoglobu-
linemia, and membranoproliferative glomerulonephri-
tis,4-6 which may also contribute to the prevalence and
severity of CKD before and after liver transplantation.
Two series have shown a high prevalence of extensive
glomerular abnormalities in renal biopsy tissue ob-
tained at the time of liver transplantation from liver
transplant recipients with and without hepatitis C.7,8
Chronic liver failure itself causes renal insufficiency
through a variety of mechanisms, including glomerular
ischemia, hepatic glomerulosclerosis, and secondary
immunoglobulin A nephropathy.
AKI
Acute deterioration in renal function is common in the
period immediately before and after liver transplanta-
tion.1,9-15 McCauley et al.9 showed that 94.3% of recip-
ients had acute renal failure, which was defined as a
50% increase in creatinine from preoperative levels. In a
series from Spain, Gainza et al.12 found acute renal
failure (serum creatinine  2.0 mg/dL or need for RRT)
in 46% of orthotopic liver transplantation (OLT) recipi-
ents in the early postoperative period. Other series from
Mount Sinai Medical Center (New York, NY) and Baylor
College of Medicine (Dallas, TX) found postoperative
RRT rates of 22% and 12% in 1602 and 724 liver trans-
plant recipients, respectively.1,15 The wide range of the
reported rates of postoperative acute renal failure is
partially due to the lack of a standard definition of acute
renal failure prior to 2004.16,17 The Acute Kidney Injury
Network and the Acute Dialysis Quality Initiative14
have developed a standard definition that can be ap-
plied in future studies. Most studies have consistently
shown that postoperative renal failure has a significant
impact on posttransplant outcomes, including mortal-
ity (Fig. 2).1,9-15 In a study by O’Riordan et al.14 in
which the Acute Dialysis Quality Initiative definitions
were employed, the 30-day mortality in subjects who
had a 3-fold increase in serum creatinine or required
RRT was 4 times greater than that in subjects with
normal serum creatinine. Postoperative acute renal
failure requiring RRT was also associated with a 2-fold
increase in hospital stay (39 versus 73 days)14 and a
5-fold increase in the duration of the postoperative in-
tensive care unit stay (2 versus 10.5 days)15 Finally,
postoperative acute renal failure was a potent risk fac-
tor for CKD in the late posttransplant period.3,18,19
CKD
The majority of liver transplant recipients who survive
beyond the first 6 months after liver transplantation
develop CKD.1-3,19-22 McCauley et al.9 reported a CKD
prevalence rate of 77.3% in OLT recipients. Gonwa et
al.3 showed that CKD (defined as serum creatinine
 2.5 mg/dL) developed in 4.9% and ESRD developed
in 5.4% of OLT recipients (n  834). In the Mount Sinai
series, Paramesh et al.1 found an incidence of ESRD of
23% at a median time of 46 months after liver trans-
plantation. In a study of 1173 OLT procedures reported
by Schmitz et al.20 from Germany, CKD, defined as
serum creatinine 1.8 mg/dL for 2 weeks, was ob-
served in 11.7% of recipients. The wide range of re-
ported incidence is partly due to the different thresh-
olds used to define CKD. In a registry study of 36,849
OLT recipients in the United States in which the Na-
tional Kidney Foundation Kidney Disease Quality Out-
comes Initiative definition of CKD23 was applied, inves-
tigators found a 5-year CKD stage IV-V incidence rate of
18.1% [stage IV CKD  estimated glomerular filtration
rate of 15-29 mL/minute/1.73 m2; stage V CKD 
ESRD].2 CKD in the liver transplant population is as-
sociated with a dramatically increased predisposition to
cardiovascular events, an increased risk of hospitaliza-
Figure 1. Biopsy-proven causes of ESRD in liver transplant
recipients (some cases had multiple histological diagnoses).
The asterisk indicates nonrecovery from pretransplant HRS.
Abbreviations: ADPKD, autosomal dominant polycystic kid-
ney disease; CNI, calcineurin inhibitor; ESRD, end-stage re-
nal disease; FSGS, focal segmental glomerulosclerosis; HRS,
hepatorenal syndrome; OLT, orthotopic liver transplantation.
Adapted from Gonwa et al.105
Figure 2. Patient survival: impact of subsequent kidney
transplantation in orthotopic liver transplantation recipients
(n  1602). Abbreviations: ESRD, end-stage renal disease; tx,
transplant. Adapted from Paramesh et al.1
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tion, and a 4-fold excess mortality in comparison with
recipients with preserved renal function.19,24-26 He-
patic allograft dysfunction has been shown to occur
more frequently in liver transplant recipients with
chronic nephropathy.27,28 Aside from a dramatic im-
pact of ESRD on mortality (4- to 5-fold higher than that
of recipients without CKD), even moderate CKD is as-
sociated with a significantly higher mortality rate. Fi-
nally, liver transplant recipients continue to experience
a high rate of recurrent AKI during the late posttrans-
plant period. In some series, the risk of AKI in the late
posttransplant period has been as high as 25% per
year, and recipients with CKD are also at a higher risk
of intercurrent CKD.
Incidence, Diagnosis, Prevention, and
Management of Acute Kidney Injury in Patients
with Cirrhosis
Russell H. Wiesner
The development of acute kidney injury (AKI) in pa-
tients with cirrhosis is a frequent and ominous event.
Indeed, renal dysfunction is a powerful predictor of
death in patients with decompensated cirrhosis.29 Se-
rum creatinine is 1 of 3 variables used in the Model for
End-Stage Liver Disease score, which is an excellent
predictor of 3-month patient survival and is currently
used for determining patient priorities for orthotopic
liver transplantation in the United States and other
countries.30 In addition, pretransplant serum creati-
nine has been found to be one of the most powerful
predictors of post–liver transplant survival.31 Thus,
preventing, identifying, and treating causes of renal
dysfunction and preserving renal function in the pa-
tient with cirrhosis are important challenges for the
liver transplant hepatologist.
CLASSIFICATION OF RENAL DYSFUNCTION
AKI occurs in approximately 20% of hepatorenal pa-
tients with cirrhosis.32,33 In patients with cirrhosis, AKI
can be classified as follows: (1) prerenal failure, (2) in-
trinsic renal disease (ie, glomerulonephritis and inter-
stitial nephritis), and (3) postrenal injury related to a
urinary obstruction (Fig. 3).34,35 The most frequent
cause of acute renal injury in patients with cirrhosis is
prerenal azotemia; this occurs because of the progres-
sive vasodilatory state of cirrhosis, which leads to rela-
tive hypovolemia and a decrease in renal blood flow,
making patients with decompensated cirrhosis very
susceptible to multiple insults to the kidney (Fig. 4).
The most common causes of prerenal azotemia include
the following: (1) sepsis, (2) gastrointestinal hemor-
rhage, (3) aggressive use of diuretics, and (4) diarrhea
related to lactulose. All of these causes may result in
additional hypovolemia resulting in further vasocon-
striction and decreased renal blood flow. In addition,
the use of nonsteroidal anti-inflammatory drugs, intra-
venous contrast, and aminoglycoside antibiotics (the
latter having a direct toxic effect on renal tubules) is
responsible for renal toxicity in a large number of pa-
tients with cirrhosis. Ultimately, hepatorenal syndrome
(HRS; a functional type of prerenal acute injury) occurs
in patients with cirrhosis who do not respond well to
volume repletion. HRS can occur suddenly and spon-
taneously (type I HRS), and it often is precipitated by
events that worsen vasodilatation, such as spontane-
ous bacterial peritonitis or a major esophageal variceal
bleed. Type I HRS carries a very dismal prognosis.36
The second type of HRS, type II, occurs more insidi-
ously and has a better prognosis but can lead to type I
HRS. Most often, however, acute renal failure in the
patient with cirrhosis is related to multiple precipitat-
ing causes, including the presence of chronic kidney
disease (CKD; eg, glomerular nephritis) and the devel-
opment of AKI in the presence of type II HRS.
Figure 3.
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CKD occurs less often and may be secondary to glo-
merulonephritis, particularly immunoglobulin A ne-
phropathy and diabetic nephropathy. Acute tubular
necrosis is also common in patients who develop shock
related to sepsis or who have experienced a major gas-
trointestinal bleed (Fig. 5). Interstitial nephritis related
to drugs and toxins is also a common cause of CKD in
patients with cirrhosis. Obstructive uropathy is a very
uncommon cause in patients with cirrhosis.
In summary, AKI occurs in approximately 20% of
hospitalized liver disease patients and is usually mul-
tifactorial, occurring in the context of a vasodilatory
state related to portal hypertension. In general, AKI
confers a poor prognosis, and the need for urgent liver
transplantation should be considered.
DIAGNOSIS
Serum creatinine is the most established, simple, and
inexpensive estimate of renal function and is the pri-
mary method of detection of all forms of renal failure.
However, there are several limitations to the use of
serum creatinine. First, serum creatinine is not helpful
in distinguishing among various causes of renal injury.
Second, serum creatinine lags behind renal injury and
is therefore a delayed marker of decreased renal func-
tion. Third, significant renal disease can exist with min-
imal or no changes in serum creatinine because of renal
reserves and enhanced tubular creatinine secretion.
Lastly, serum creatinine is influenced by nonrenal fac-
tors such as body weight, muscle mass, race, age, gen-
der, total body volume, and protein intake. The optimal
method for measuring renal function is probably deter-
mination of the glomerular filtration rate with iothalamate
or inulin clearance methods.
The differentiation of types of AKI can be aided by the
following parameters: (1) urinalysis and microscopy of
urinary sediment, (2) urinary sodium, (3) fractional so-
dium excretion, (4) osmolarity, and (5) biological mark-
ers. The differentiation of HRS, acute tubular necrosis,
and glomerulonephritis is outlined in Fig. 5.
PREVENTION AND TREATMENT
Specific therapies used to treat renal injury depend on
the cause. Prophylaxis and prevention of acute renal
injury play important roles in the management of pa-
tients with cirrhosis and particularly those patients on
the liver transplantation waiting list. Prophylactic ther-
apy to prevent variceal bleeding and spontaneous bac-
terial peritonitis is an important preventative measure.
In addition, close monitoring of diuretic therapy and
titration of the dose of lactulose to prevent severe diar-
rhea are also important preventative measures. The use
of albumin with large-volume paracentesis and antibi-
otic treatment of spontaneous bacterial peritonitis are
important therapeutic measures to prevent renal dam-
age.37-39 The avoidance of nonsteroidal anti-inflamma-
tory drugs, aminoglycoside antibiotics, and intrave-
nous contrast are important measures to consider in
the management of a decompensated patient with cir-
rhosis. Although not very well described, abdominal
Figure 4. Abbreviations: GI,
gastrointestinal; HRS, hepato-
renal syndrome; NSAID, nonste-
roidal anti-inflammatory drug.
Figure 5. Diagnosis of acute re-
nal injury. Abbreviations: ATN,
acute tubular necrosis; Fx, frac-
tional; GN, glomerulonephritis;
HRS, hepatorenal syndrome;
RBC, red blood cell.
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compartment syndrome due to increased intra-abdom-
inal pressure secondary to ascites should also be con-
sidered when AKI is being evaluated in patients with
cirrhosis.
In patients developing prerenal azotemia, removal of
the precipitating factors and volume replacement with
albumin are important. Renal replacement therapy
should be considered in those patients who develop
hypovolemia, uremia, hyperkalemia, and acidosis. In
patients developing HRS, the use of systemic vasocon-
strictor therapy with terlipressin plus albumin or nor-
adrenalin combined with albumin has been known to
reverse HRS in some patients.40-42 This can buy some
time to find an acceptable donor for liver transplanta-
tion. The old myths regarding HRS, which state that the
kidneys are normal, that recovery of renal function is
immediate, and that complete recovery of renal func-
tion will occur, are not necessarily true in all patients
with HRS; HRS may lead to permanent damage, partic-
ularly in patients with cirrhosis who experience pro-
longed renal dysfunction.36 In these patients, a simul-
taneous kidney transplant may be indicated.43 The use
of systemic vasoconstrictor therapy associated with al-
bumin is now undergoing testing in patients with non-
HRS acute renal injury.44 Furthermore, newer thera-
pies such as transjugular intrahepatic portosystemic
shunts and the use of a molecular absorbent recircu-
lating system with albumin have also been shown to be
of benefit in patients with prerenal azotemia and in
patients with HRS.45,46 The use of renal replacement
therapy for acute tubular necrosis and the use of inter-
mittent hemodialysis versus continuous venous filtra-
tion remain controversial at this time, and more data
are needed.47
Hepatorenal Syndrome: Clinical Features,
Management, and the Role of Liver
Transplantation
Andrés Cárdenas and Pere Ginès
Hepatorenal syndrome (HRS) is a potentially reversible
cause of renal impairment that occurs in patients with
cirrhosis and ascites and in patients with acute liver
failure or alcoholic hepatitis.48,49 HRS is characterized
by impaired renal function, marked alterations in car-
diovascular function, and overactivity of the sympa-
thetic nervous and renin-angiotensin systems, which
lead to severe renal vasoconstriction with a significant
decrease of the glomerular filtration rate (GFR) to 30
mL/minute.48,49 HRS occurs in approximately 10% of
hospitalized patients with cirrhosis and ascites.50 In
this section, we describe the clinical features, diagno-
sis, and management of HRS with a specific emphasis
on the role of liver transplantation (LT) as a therapy for
HRS.
CLINICAL FEATURES
There are no specific clinical findings in HRS. The ma-
jority of patients have features of very advanced liver
disease with hyperbilirubinemia, an elevated prothrom-
bin time, thrombocytopenia, hepatic encephalopathy,
hypoalbuminemia, hyponatremia, and a large amount
of ascites. In some patients, HRS develops spontane-
ously without any apparent triggering event, whereas in
others, it occurs in close relationship with events that
impair circulatory function, such as bacterial infection
(particularly spontaneous bacterial peritonitis), which
may precipitate HRS in approximately 40% of cases.51,52
Renal failure is common in patients with cirrhosis and
gastrointestinal bleeding, occurring in 11% of cases,
but in this setting, renal failure is usually due to renal
hypoperfusion with or without acute tubular necrosis
related to hypovolemic shock and not to HRS.53
There are 2 different clinical types of HRS, type 1 and
type 2, which have previously been defined by the In-
ternational Ascites Club.48,49 In type 1 HRS, renal func-
tion deteriorates rapidly with an increase in serum cre-
atinine to a level higher than 2.5 mg/dL in less than 2
weeks. In these patients, GFR is very low, commonly
below 20 mL/minute, and serum creatinine levels are
high, with average values of 4 to 5 mg/dL at the time of
diagnosis. This type of HRS, if not treated, is associated
with a very poor prognosis with a median survival of 2 to
4 weeks.50,54 In type 2 HRS, there is a steady decline in
renal function, and serum creatinine levels usually
range from 1.5 to 2.5 mg/dL. Survival in patients with
type 1 HRS is not dependent on the Model for End-
Stage Liver Disease (MELD) score; that is, patients have
very poor survival regardless of the MELD score. Pa-
tients with type 2 HRS have a better prognosis than
those with type 1 HRS, with a median survival of 6
months. In patients with type 2 HRS, survival is depen-
dent on the MELD score: those with a score  20 have
a poor outcome versus those patients with a MELD
score  20.54 The diagnosis of HRS relies on the exclu-
sion of other conditions that may cause renal failure
in cirrhosis, particularly volume depletion, shock,
treatment with nephrotoxic drugs, and parenchymal
kidney diseases.48,49 The diagnostic criteria recently
revised by the International Ascites Club are shown
in Table 1.49
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MANAGEMENT
The most important aspect of providing care to patients
with HRS is the assessment of candidacy for orthotopic
LT. Currently available therapies other than LT for HRS
include the use splanchnic vasoconstrictors and albu-
min and transjugular intrahepatic portosystemic shunt
(TIPS).
Vasoconstrictors
The administration of vasoconstrictors is the best med-
ical therapy currently available for the management of
HRS. The rationale of this therapy is to improve circu-
latory function through vasoconstriction of the ex-
tremely dilated splanchnic arterial bed, which subse-
quently improves arterial underfilling, reduces the
activity of the endogenous vasoconstrictor systems,
and increases renal perfusion. The available vasocon-
strictors used for HRS are vasopressin analogues (ter-
lipressin) and -adrenergic agonists (noradrenaline or
midodrine), which act on V1 vasopressin receptors and
-1 adrenergic receptors, respectively, present in vas-
cular smooth muscle cells. In most studies, vasocon-
strictors have been given in combination with intra-
venous albumin to further improve the arterial
underfilling. Most of the published data come from the
use of intravenous terlipressin for type 1 HRS. Results
from 2 recent randomized controlled studies indicate
that treatment with terlipressin together with albumin
is associated with marked improvement of renal func-
tion in approximately 40% of patients.55,56 Previous
uncontrolled studies suggested a higher response rate
(50%-75%).2 Although there are no dose-efficacy stud-
ies, treatment is usually started with 0.5 to 1 mg every
4 to 6 hours intravenously, and the dose is increased up
to a maximum of 2 mg every 4 to 6 hours after 2 days if
there is no response to therapy (response to therapy is
defined as a reduction of serum creatinine  25% of the
pretreatment values). Response to therapy is consid-
ered when there is a marked reduction of the high
serum creatinine levels, at least below 1.5 mg/dL,
which is usually associated with increased urine out-
put and improvement of hyponatremia. The incidence
of ischemic side effects requiring the discontinuation of
treatment is approximately 10%. Some patients may
develop transient pulmonary edema during the first few
days of therapy. The 2 aforementioned randomized
studies55,56 showed that the overall population of pa-
tients treated with terlipressin and albumin did not
have improved survival in comparison with the popula-
tion of patients treated with albumin alone. However,
both studies showed that responders in terms of im-
provement of renal function after therapy had a signif-
icant (but moderate) increase in survival in comparison
with nonresponders. In one study, patients that re-
sponded to therapy had a 3-month probability of sur-
vival of 58% versus 15% in those that did not respond to
therapy (median survival greater than 90 days versus
13 days, respectively, P  0.03).56 However, it is impor-
tant to highlight that the improvement in survival is
subtle, and this means that responders still have a high
risk of death while awaiting transplantation and, there-
fore, should continue as priority candidates, although
their MELD score may decrease after therapy. Factors
associated with poor response include a bilirubin
level 10 mg/dL and a leukocyte count  9500/mm3
before therapy.57 -Adrenergic agonists (noradrenaline
and midodrine) represent an attractive alternative to
terlipressin because of their low cost, wide availability,
and apparently similar efficacy in comparison with ter-
lipressin.58-60 However, information on the efficacy and
side effects of -adrenergic agonists in patients with
type 1 HRS is still very limited.
There are limited data on the use of vasoconstrictors
plus albumin for patients with type 2 HRS. However,
data from uncontrolled studies suggest that they are
effective in decreasing serum creatinine levels in these
patients. In 2 controlled studies, patients with type 2
HRS that received terlipressin plus albumin had a re-
sponse rate between 67% and 88%; however, few were
treated with this strategy in both studies (n  13), and
therefore more controlled studies are needed in order to
better define the role of vasoconstrictors plus albumin
in the management of type 2 HRS.56,61
TIPS
Two uncontrolled studies indicate that TIPS may im-
prove renal function and GFR and reduce the activity of
the renin-angiotensin-aldosterone system and the sym-
pathetic nervous system in patients with type 1
HRS.45,62 Improvement in renal function after TIPS
placement alone is slow and successful in approxi-
mately 60% of patients.45,62 Studies assessing TIPS for
type 1 HRS have included only patients with moderate
to severe liver failure and excluded those with a history
of hepatic encephalopathy, Child-Pugh scores  12, or
serum bilirubin  5 mg/dL. The applicability of TIPS in
patients with type 1 HRS is low because TIPS is consid-
ered contraindicated in patients with features of severe
liver failure, which are common findings in the setting
of type 1 HRS. The use of TIPS in type 2 HRS may
improve renal function and reduce the risk of progres-
TABLE 1. Diagnostic Criteria for Hepatorenal
Syndrome in Cirrhosis
1. Cirrhosis with ascites
2. Serum creatinine  1.5 mg/dL (133 mol/L)
3. No improvement of serum creatinine [a decrease to
1.5 mg/dL (133 mol/L)] after at least 2 days off
diuretics and volume expansion with albumin (1 g/
kg of body weight up to a maximum of 100 g/day)
4. Absence of shock
5. No current or recent treatment with nephrotoxic
drugs
6. Absence of signs of parenchymal renal disease, as
suggested by proteinuria (500 mg/day) or
hematuria (50 red blood cells per high-power
field), and/or abnormal renal ultrasound
NOTE: This table was adapted from Salerno et al.49
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sion to type 1 HRS.45,63,64 However, a subanalysis of
patients with type 2 HRS included in a controlled study
comparing TIPS and repeated paracentesis plus albu-
min in patients for refractory ascites showed that
the use of TIPS was not associated with improved
survival.63
Renal Replacement Therapy (RRT)
RRT, mainly hemodialysis, has been used in the man-
agement of patients with type 1 HRS, especially in pa-
tient candidates for LT, in an attempt to keep patients
alive until LT is performed or a spontaneous improve-
ment in renal function occurs.65 Unfortunately, the po-
tential beneficial effect of this approach has not been
demonstrated. Most patients develop side effects dur-
ing RRT, including severe arterial hypotension, bleed-
ing, and infections, that may contribute to death during
treatment. Additionally, indications for RRT (severe
fluid overload, acidosis, or hyperkalemia) are uncom-
mon in type 1 HRS, at least in the early stages.
LT
LT is the treatment of choice for patients with cirrhosis
and HRS, either type 1 or type 2. However, a main
limiting factor of LT for type 1 HRS is the high mortality
rate on the waiting list due to the combination of short
survival expectancy and prolonged waiting times in
many transplant centers. This limitation can be over-
come if these patients are assigned a high priority for
transplantation. The short survival of patients with
type 2 HRS (median of 6 months) should also be taken
into account when these patients are assessed for LT.
There are 4 management approaches when LT is con-
sidered for patients with HRS. One is LT alone because
when patients are transplanted with severe renal fail-
ure, they usually require more days in the intensive
care unit and longer hospitalizations in comparison
with patients without HRS. Moreover, RRT require-
ments are high during the first weeks after LT but de-
cline thereafter, yet 10% of patients may need RRT after
6 weeks.66,67 The second approach that has been ad-
vocated for patients with HRS is combined liver-kidney
transplantation (CLKT). Since the introduction of the
MELD score system for organ allocation in the United
States, there has been an increase in the use of CLKT
for patients with cirrhosis and renal failure, which has
been associated with a decline in survival after CLKT in
comparison with the preceding years.67-70 Moreover,
the outcome of patients with HRS treated with CLKT is
not better than that of patients with HRS treated with
LT alone.68 In addition, this approach uses kidneys
that could be used for patients with chronic renal fail-
ure without liver disease, who have prolonged waiting
times for renal transplantation. All these factors, to-
gether with the fact that renal function in HRS patients
usually recovers after LT alone, suggest that CLKT is
not a good approach for the management of patients
with HRS. The only exception may be patients with HRS
who have been on RRT for more than 8 weeks.70 The
third strategy is the performance of LT alone followed by
kidney transplantation if necessary. With this ap-
proach, kidney transplantation is performed in patients
who undergo LT for HRS and require RRT more than 60
days after LT. Data on this approach are limited to only
one study, and thus more studies are needed in order to
consider this strategy acceptable.71 The final strategy is
the treatment of HRS with vasoconstrictors plus albu-
min while the patient is on the waiting list and subse-
quently LT. Because pretransplant renal failure is an
independent risk factor for both short-term and long-
term posttransplantation patient and graft survival, all
efforts should be made to improve renal function in
order to obtain a better outcome after transplanta-
tion.72 The reversal of both type 1 and 2 HRS before
transplantation may not only help patients reach trans-
plantation but also reduce the relatively high morbidity
and mortality after LT characteristic of HRS. Therapy of
HRS with terlipressin before LT leads to similar and
slightly better 3-year survival than therapy without
HRS (100% versus 83%).73 However, data are limited,
only 40% of patients respond to terlipressin, MELD
scores may decrease with therapy, and patients may
experience side effects in 10% of cases; therefore, more
studies and a longer follow-up period still are needed to
determine whether pre-LT therapy of HRS actually will
translate into better post-LT outcomes.
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Mechanisms of Nephrotoxicity of
Immunosuppressive Drugs
Fuad S. Shihab
The perfect immunosuppressive drug would be able to
suppress the alloimmune response while avoiding tox-
icity. Unfortunately, none of the currently available
drugs fit the bill, and most are characterized by a nar-
row therapeutic index in addition to broad interindi-
vidual variability. Cyclosporine A (CsA) is the perfect
example of a drug that has revolutionized the field of
transplantation by decreasing the incidence of acute
rejection and improving short-term graft survival. How-
ever, its clinical use has been greatly limited by neph-
rotoxicity, which affects renal function and long-term
renal graft survival. Most data in this field pertain to
CsA, although the effects of tacrolimus (Tac) are
thought to be similar. Two forms of calcineurin inhibi-
tor (CNI) renal toxicity have been described: acute and
chronic nephrotoxicity. In kidney transplantation, it is
often difficult to dissociate nephrotoxicity mechanisms
from other immune and non–immune-mediated events
that lead to graft fibrosis. As a result, nephrotoxicity is
best studied in nonrenal organ transplantation in ad-




CsA and Tac cause vasoconstriction of the afferent and
efferent glomerular arterioles and reduce the renal
blood flow and ultrafiltration coefficient and, as a re-
sult, the glomerular filtration rate. Acute CNI nephro-
toxicity is usually reversible with cessation of therapy.
The precise mechanism of vasoconstriction is un-
clear, but we know that there is an imbalance in vaso-
active substances leading to reduced production of va-
sodilators such as nitric oxide and prostaglandins and
enhanced release of vasoconstrictors such as endothe-
lin (ET), thromboxane, and angiotensin II (Fig. 6). In-
creased sympathetic tone is also present, although va-
soconstriction occurs even in denervated kidneys.
Increased vascular resistance is clinically reflected by
elevated serum creatinine and hypertension. These
complications are more likely to occur with prolonged
ischemia and high CNI doses but can also be seen with
therapeutic levels.
These functional abnormalities are associated with
increased urinary ET excretion. Studies with ET-R an-
tagonists suggest that ET mediates CNI-induced affer-
ent arteriolar vasoconstriction.74 Calcium channel
blockers can prevent renal vasoconstriction but not ET
excretion, and this suggests that vascular injury is still
occurring. Rarely, idiosyncratic vascular lesions similar
to hemolytic uremic syndrome are seen, presumably
because of CNI-induced injury to endothelial cells.
Injury Manifested as Vasculopathy or
Tubulotoxicity
The chronic form of CNI nephrotoxicity is characterized
by the development of structural damage that is irre-
versible and may lead to end-stage renal disease. His-
tologically, there is an obliterative arteriolopathy, glo-
merular ischemic collapse and scarring, tubular
vacuolization, and focal areas of tubular atrophy and
interstitial fibrosis (striped fibrosis). These changes are
seen with both low and higher dose CsA therapy, al-
though they seem to occur earlier with higher doses. It
has been proposed that the arterial lesion is the pri-
mary abnormality, with secondary ischemia being re-
sponsible for the tubular and interstitial lesions. This is
supported by animal studies in which the vascular and
interstitial findings can be dissociated.
The factors responsible for chronic CNI nephrotoxic-
ity are not well understood (Fig. 7). The renin-angioten-
sin-aldosterone system is up-regulated in experimental
models of chronic CNI nephrotoxicity, although there is
no evidence that it is activated in humans. Angiotensin
II, through activation of AT1 receptors, not only partic-
ipates in renal vasoconstriction but also promotes fi-
brosis either directly by up-regulating transforming
growth factor  (TGF-) or through other independent
mechanisms.75 Renal hypoxia, which results from re-
nal vasoconstriction, leads to the formation of reactive
oxygen species that cause cellular injury and promote
cellular death by apoptosis. Increased apoptosis occurs
in kidneys exposed to CNIs, and this potentially ex-
plains the loss of cells that accompanies fibrosis, which
impairs the ability of the kidney to remodel effectively.
The expression of apoptotic genes, such as p53 and Fas
ligand, is enhanced in rats administered CsA in a man-
ner favoring the induction of apoptosis.76
The development of interstitial fibrosis is also associ-
ated with increased expression of the macrophage che-
moattractant osteopontin and a number of chemo-
kines. However, it is the up-regulation of TGF-
expression that has taken center stage, and this is
supported by considerable experimental evidence.77
The profibrotic actions of TGF- include stimulation of
extracellular matrix (ECM) synthesis, inhibition of ECM
degradation, and modulation of ECM receptor expres-
sion to facilitate cell-ECM interactions. The role of
TGF- in chronic CsA nephrotoxicity has been sup-
ported by experimental findings in which the lesion was
significantly diminished with anti–TGF- therapy.78
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Another antifibrotic agent, pirfenidone, which is thought
to inhibit TGF- actions, has been shown to significantly
inhibit fibrosis by approximately 50% in CsA-treated
rats.79 TGF- appears to be induced in part by decreased
secretion of nitric oxide as well as increased local concen-
trations of angiotensin II, and this possibly explains the
beneficial effects observed with angiotensin-converting
enzyme inhibitors and angiotensin II receptor antago-
nists.80 Blockade of aldosterone receptors has also been
successful in ameliorating CsA nephropathy, at least
partly by decreasing TGF-.81
In addition, mycophenolate mofetil was capable of
improving arteriolopathy in CsA-treated rats and de-
creased TGF- but did not affect renal function.82 A list
of pharmacological treatments used to reduce or pre-
vent chronic CNI nephrotoxicity is shown in Table 2. It
is to be noted that none of the interventions are entirely
successful in improving renal function or reducing fi-
brosis, and this suggests that a number of mechanisms
are likely to be involved.
NEPHROTOXICITY OF MTOR INHIBITORS
In the absence of concomitant CNIs, mammalian target
of rapamycin (mTOR) inhibitors do not seem to have
significant nephrotoxicity in most animal and human
studies. However, when they are combined with a CNI,
serum creatinine levels often increase. Furthermore,
clinical data have shown that the administration of
sirolimus (SRL) after renal transplantation impairs re-
covery from delayed graft function, possibly because of
inhibition of renal tubular cell proliferation, which nor-
mally occurs in tubular repair. A characteristic cast
nephropathy lesion has also been reported. Proteinuria
has been shown to occur with long-term use of SRL and
may be related to a decrease in tubular reabsorption
and/or podocyte dysregulation. Vascular endothelial
growth factor is increased in this setting, and a lesion of
collapsing focal segmental glomerulosclerosis has also
been reported. In addition to a pharmacokinetic inter-
action raising CsA blood trough levels, there seems to
be a CsA-SRL interaction occurring at the cellular level
and resulting in enhanced nephrotoxicity. Both CsA
and SRL are P-glycoprotein (P-gp) substrates (dis-
cussed later), and in human renal epithelial cells, inhi-
bition of P-gp–mediated efflux by SRL leads to increased
cellular concentrations of CsA that could explain, at
least partly, the exacerbation of CsA nephrotoxicity.83
In addition, SRL has been shown to increase TGF-
expression in experimental CsA nephrotoxicity.84 The
experience with the new mTOR inhibitor everolimus is
limited, but similar increases in serum creatinine when





Therapeutic drug monitoring is widely applied for the
management of immunosuppressive drugs. It allows for
individualized dose administration in an attempt to op-
timize safety and efficacy. Drug pharmacokinetics are
affected by processes such as bioavailability, volume of
distribution, binding, and elimination. Most of the time,
drug exposure is best studied by the determination of
the area under the concentration-time curve (AUC). In
the case of CsA, an AUC0-4 of 4400 to 5500 mg h/L or
Figure 6. Abbreviations: CsA,
cyclosporine A; Kf, glomerular
capillary ultrafiltration coeffi-
cient; QA, single glomerular
plasma flow rate; SNGFR, single
nephron glomerular filtration
rate.
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an AUC0-12 of 9500 to 11,500 mg h/L best defines the
therapeutic window below which the risk of rejection is
increased and above which the risk of nephrotoxicity is
increased.85 Unfortunately, CsA trough levels do not
correlate well with AUC. This correlation is better with
Tac but is not perfect. Because routine AUC measure-
ments are cumbersome, clinicians continue to use the
imperfect measure of CNI blood trough levels. Built into
this is a major assumption: the concentration of the
drug in the blood or serum is related to the concentra-
tion of free drug at its effector site in the tissue. How-
ever, this may not always be true, as shown in routine
hepatic biopsies performed in 146 liver transplant re-
cipients: tissue levels displayed an excellent correlation
with liver histological Banff rejection scores (R2  0.98),
whereas blood levels did not.86
Figure 7. Abbreviations: ROS,
reactive oxygen species; TGF-,
transforming growth factor .
TABLE 2. Select Pharmacological Interventions for Cyclosporine A Nephrotoxicity
Treatment Improvement of Renal Function Reduction of Renal Fibrosis
Nifedipine No ND
Thromboxane synthase inhibitor No ND
ET-A/B-R blocker 30% No




Pentosan polysulfate No 45%
Leukotriene receptor antagonist 65% ND
Oral magnesium No ND




Mycophenolate mofetil No 2 Arteriolopathy
Anti–TGF- ND 40%
TGF-RII/IgG Fc ND 60%
Sirolimus Worse Worse
Pravastatin 75% 55%
Hepatocyte growth factor No 25%
Abbreviations: ET, endothelin; Fc, fragment crystallizable; IgG, immunoglobulin G; ND, not determined; TGF-, transforming
growth factor .
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In addition, some patients seem to be particularly sus-
ceptible to CNI nephrotoxicity. CNIs are substrates for
P-gp, an efflux pump that protects cells from environmen-
tal toxins. There is some evidence that decreased expres-
sion of P-gp may contribute to increased CsA tissue levels,
leading to nephrotoxicity. In addition, there may also be
an intrinsic renal susceptibility to CsA-induced renal va-
soconstriction. Experimental support for this hypothesis
is derived from a study of 8 pairs of stable, unrelated renal
transplant recipients receiving a deceased donor kidney
from the same donor. Although there was a parallel re-
sponse to increasing CsA dose, 4 pairs showed an eleva-
tion in plasma creatinine, whereas 3 pairs showed no
change (P  0.05).
Pharmacogenomics could also explain 20% to 95% of
the variability encountered not only in drug disposition
and targets but also in side effects. This applies, for ex-
ample, to the adenosine triphosphate–binding cassette
B1 gene that encodes for the P-gp protein.87,88 In addi-
tion, the P450 cytochromes (CYPs) play a key role in the
metabolism of CNIs and mTOR inhibitors and are ex-
pressed in the liver and intestine. Although the influence
of genetic polymorphism on CsA pharmacokinetics re-
mains a source of contention, CYP3A5 polymorphism is
undoubtedly closely associated with Tac disposition.
CONCLUSIONS
The mechanisms involved in the nephrotoxicity of im-
munosuppressive drugs remain poorly understood,
and numerous mediators are likely to be involved. In
addition, the success of transplantation remains
largely dependent on the use of CNIs because the suc-
cess of CNI-free regimens has been very limited. How-
ever, identification of elements that predispose patients
to drug-related nephrotoxicity constitutes a major im-
provement and may offer a promising new approach to
assess individual risk and select treatment according to
patient parameters. Finally, studies of the genetic basis
of interindividual variability in the pharmacokinetics
and effects of immunosuppressive agents may optimize
dosing strategies for immunosuppressive drugs after
organ transplantation in the future.
APPROACHES TO THE MANAGEMENT OF RENAL INSUFFICIENCY IN LIVER TRANSPLANT RECIPIENTS
Evaluation and Pharmacotherapy of
Calcineurin Inhibitor Toxicity
Stephen Textor
Calcineurin inhibitors (CNIs), including cyclosporine and
tacrolimus, have been a fundamental component of im-
munosuppression for solid organ transplantation for
more than 25 years. These agents regularly induce renal
vasoconstriction and reduce the glomerular filtration rate
(GFR). GFR typically falls 30% to 35% during the first
weeks after CNI therapy is started in nonrenal transplan-
tation. Cyclosporine has been most widely studied, but
the effects of tacrolimus are similar, albeit less rapid and
less severe.
EARLY AFTER TRANSPLANTATION (1-6
MONTHS)
CNIs rapidly alter hemodynamic factors within both
systemic and renal circulations. These effects include a
reduction in vasodilation (eg, prostacyclin and nitric
oxide) and enhanced vasoconstriction (thromboxane A2
and endothelin).89,90 Studies in human subjects using
cyclosporine have indicated that this effect develops in
a dose-dependent and time-dependent fashion within
hours after each dose.91 In some experimental models,
sympatho-adrenergic activity is increased.92 The net
vasoconstrictor effect raises systemic vascular resis-
tance, producing a rise in arterial pressure, and re-
duces renal blood flow and filtration. These early vas-
cular changes are dose-dependent and reversible if the
CNI is reduced or withdrawn. Clinicians recognize that
preexisting hemodynamic compromise and/or intrinsic
renal disease may magnify the nephrotoxic effects of
CNIs. The evaluation of reduced renal function in this
period focuses on the identification and removal of
these additional factors when possible. These include
identification of drug-drug interactions that change
CNI levels. Drug interactions leading to elevated CNI
levels are particularly common with antifungal therapy
(ketoconazole, voriconazole, and itraconazole) and
highly active antiretroviral therapy. Importantly, condi-
tions producing relative volume depletion, hypotension,
sepsis, and other nephrotoxic drugs magnify CNI neph-
rotoxicity. Chronic conditions predisposing to intravas-
cular volume depletion, such as an ileostomy, chronic
diarrheal states, and bladder-drained pancreas allo-
grafts, routinely reduce GFR, sometimes accelerating
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the need for renal replacement or kidney transplanta-
tion. The aggressive administration of diuretic therapy
after organ transplantation may accelerate this pro-
cess.
Many patients treated with CNIs demonstrate mod-
erate tubular dysfunction reflected by impaired acidifi-
cation (renal tubular acidosis), magnesium wasting,
and impaired potassium secretion (hyperkalemia).
These are usually self-limited. During the early period
after transplantation, a predilection for hyperkalemia
can limit the use of trimethoprim-sulfa and/or agents
that block the renin-angiotensin system, such as an-
giotensin-converting enzyme (ACE) inhibitors and an-
giotensin receptor blockers. In view of the multiple fac-
tors affecting both potassium and creatinine early after
kidney transplantation, our practice is to avoid the rou-
tine use of ACE inhibitors and angiotensin receptor
blockers for the first several months.
LATE AFTER TRANSPLANTATION (BEYOND 6
MONTHS)
Continued administration of CNIs eventually produces
changes in glomerular filtration that no longer reverse
after withdrawal of the drugs. Identification of irrevers-
ible nephrotoxicity depends on a biopsy demonstration
of hyaline accumulation, vascular obliteration, and re-
gional ischemia (striped fibrosis) and the exclusion of
other lesions. Follow-up studies indicate that up to 17%
of nonrenal solid organ transplant recipients (liver,
heart, lung, and intestine) eventually develop stage 4
chronic kidney disease (CKD; estimated GFR  29 mL/
minute/1.73 m2) during a mean follow-up of 37
months.2 About 30% of these eventually progress to the
need for renal replacement therapy, including kidney
transplantation or dialysis. How best to identify indi-
viduals predisposed to developing ongoing renal injury
that will accelerate during CNI exposure after trans-
plantation remains problematic.93,94 When GFR is re-
duced on the basis of hemodynamic changes primarily
associated with organ failure, such as congestive heart
failure or liver failure, it may improve substantially after
hemodynamics recover with successful transplanta-
tion.93 Many of these patients do not require combined
liver-kidney or heart-kidney transplants.95 It should be
recognized that other forms of parenchymal renal in-
jury may also coexist with advanced organ failure. Such
intrinsic kidney pathology likely will affect the nephro-
toxicity of CNIs and accelerate the loss of GFR after
organ transplantation. Many patients with hepatitis C,
for example, have evident immune complex deposition
on kidney biopsy at the time of liver transplantation.8
Over the long term, reduced GFR during CNI adminis-
tration can develop for many reasons. Important causes
include vascular occlusive disease, primary parenchy-
mal diseases, including posttransplant diabetic ne-
phropathy, immune complex diseases, and BK ne-
phropathy. The last remains a significant problem (with
a reported rate of 2%-5%) in kidney transplantation,
but it also can occur in nonrenal transplants. Progres-
sive loss of GFR primarily related to CNI use can be
observed. Reduced GFR 1 year after solid organ trans-
plantation remains a strong predictor of long-term
nephrotoxicity and the development of progressive
CKD. An evaluation should include studies to evaluate
the renal circulation and the magnitude of proteinuria
and to exclude outflow tract obstruction. Kidney biopsy
should be considered when the explanation is unclear
and/or significant proteinuria is detected.
PHARMACOTHERAPY OF CNI
NEPHROTOXICITY
CNI dose reduction remains the mainstay of avoiding
major progression. Dihydropyridine calcium channel
blocking drugs effectively reduce systemic vasocon-
striction (and therefore arterial pressure) but do not
consistently increase renal blood flow or GFR. During
early phases of vasoconstriction, blockade of the renin-
angiotensin system (with ACE inhibition or angiotensin
receptor blockers) has little effect in human studies,
although long-term activation of this system increases
their effectiveness for antihypertensive therapy after
the first year. Animal models of CNI toxicity indicate
that renin-angiotensin blockade reduces kidney fibro-
sis.96 Although these agents lower proteinuria in sub-
jects with glomerular disease, no specific benefits have
been demonstrated in humans with respect to kidney
function after nonrenal transplantation. Although hu-
man data are limited to uncontrolled observations, the
use of ACE inhibition in conjunction with CNIs as a
means of avoiding nephrotoxicity may provide immu-
nological protection while mitigating toxicity and, in the
long term, may be a more durable strategy than mini-
mizing immunosuppression. Some studies suggest that
amplification of vasodilator systems such as endoge-
nous nitric oxide by the provision of excess substrate
(L-arginine) can reverse the effects of cyclosporine.97
Whether this strategy has clinically beneficial effects in
patients with CNI nephrotoxicity is not yet known.
Complete withdrawal of CNIs has been undertaken,
sometimes with substitution using alternative non-CNI
immunosuppression such as sirolimus. Reports of car-
diac transplant recipients with a measured GFR of 36 
2 mL/minute indicated that follow-up GFR rose to
48.7  4 mL/minute after 12 months.98 In some cen-
ters, long-term GFR is somewhat improved when a
transition away from a CNI (cyclosporine) is achieved 3
to 6 months after the initial transplant.99 Other expe-
rience with sirolimus has been mixed. A long-term,
prospective, randomized comparison of tacrolimus-
based and sirolimus-based regimens (CNI-free at all
times) achieved similar levels of GFR, similar graft out-
comes, and similar levels of hypertension with the 2
regimens.100,101 Sirolimus has been associated with
nephrotoxicity in its own right and often worsens pro-
teinuria in patients with developing parenchymal kid-
ney disease.102,103 Hence, this agent should not be
used in patients with worsening proteinuria.
Recent trends suggest that requirements for kidney
transplantation after other solid organ transplants may
be stabilizing despite the migration to solid organ trans-
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plantation with more advanced kidney disease.25,104
Careful avoidance of transient episodes of volume de-
pletion or high blood levels can allow the safe use of
CNIs for many years. Nonetheless, the “therapeutic
window” of CNIs remains distressingly narrow. Im-
proved methods for monitoring and minimizing neph-
rotoxic and vascular effects of these agents on the kid-
ney are sorely needed.
Renal-Sparing Protocols in Liver Transplantation
Paul J. Marotta
Renal dysfunction is an exceedingly common and sig-
nificant problem after liver transplantation. Renal im-
pairment may start or already preexist in the early post-
transplant period and may then progress as the years
from transplantation march on. The renal impairment
suffered by liver transplant recipients has only recently
become increasingly apparent and has a clear impact
on transplant recipients’ overall quality of life, in addi-
tion to the evidence revealing a significant insult to
these patients’ overall morbidity and potential mortal-
ity. The cumulative incidence of chronic kidney disease
(CKD) in the post–liver transplant recipient has been
made evident by several authors, and no report has
been more sobering than the one by Ojo et al.,2 who not
only detailed an alarming 18.1% incidence of CKD only
5 years after liver transplantation but additionally re-
ported that renal dysfunction is a progressive and cu-
mulative complication in all organ transplant recipi-
ents. The impact is significant, such that the presence
of chronic renal failure in nonrenal transplant recipi-
ents is associated with a risk of death increased by a
factor of more than 4.
Immunosuppressive therapy given after liver trans-
plantation typically includes a calcineurin inhibitor
(CNI). These agents have been used widely for several
decades in the field of liver transplantation and have
been responsible for the impressive increments in
both patient and graft long-term survival. Despite the
tremendous gains provided by CNIs, it has become
increasingly clear that these agents are linked intrin-
sically to nephrotoxicity through vasoconstriction
mechanisms and through other potential renal dam-
aging adverse effects, namely hypertension, hyperlip-
idemia, and diabetes mellitus. This combined adverse
effect profile has been implicated as the principle
cause of progressive renal impairment after solid or-
gan transplantation.105 The nephrotoxicity related to
the use of CNIs is not related to either the overall
dosage or the trough blood levels produced.106,107
Questions remain about whether the degree of
chronic renal impairment or its progression can be
either prevented or potentially reversed with the ma-
nipulation of CNI agents. Worldwide, liver transplant
programs have struggled to identify immunosuppres-
sive protocols that continue to have the benefit of low
rejection rates, excellent patient and graft survival,
and limited short-term and long-term toxicity. Sev-
eral other immunosuppressive agents have been de-
veloped in an attempt to “spare” the kidney from
toxicity. These agents have been used increasingly to
overcome CNI toxicity.108,109 They include mycophe-
nolate mofetil (MMF) and mammalian target of rapa-
mycin (mTOR) inhibitors (sirolimus and everolimus)
and have proven efficacy in the field of liver trans-
plantation.110 Hence, despite the importance of the
CNI class of immunosuppressive agents, combina-
tions of other immunosuppressants are being used in
an attempt to affect and potentially reverse renal im-
pairment.
Although there is clear recognition that the etiology of
chronic renal failure is multifactorial, the renal effect of
CNIs does remain the key component. Immunosup-
pressive protocols have been developed and studied,
with the main outcome measure being the impact on
renal function. These renal-sparing strategies include
the following:
1. The reduction or complete withdrawal of the CNI.
This is typically accomplished with the introduction
of an adjuvant agent such as MMF or azathioprine
or, alternatively, the complete discontinuation of
the CNI with the use of MMF monotherapy.
2. The conversion of primary CNI-based therapy to a
non–CNI-based therapy such as one using siroli-
mus with MMF.
3. The use of antibody induction therapy in an at-
tempt to delay the initiation of CNI-based therapy.
Renal impairment unfortunately is not easy to recog-
nize in the early stages. Despite the poor correlation of
serum creatinine to underlying renal function, this
marker is often the only value on which physicians act,
often well after the onset of true renal impairment.111-113
Given the importance of long-term renal function in
liver transplant recipients, it is not surprising that
many clinical studies are now focused on accurately
measuring renal function longitudinally. The challenge
has been in selecting the most appropriate outcome
measure and an adequate period of follow-up. Given the
limitation of longitudinally measuring the glomerular
filtration rate (GFR) in patients, the calculated GFR has
been a reasonable surrogate marker and is most often
the main outcome measure followed in clinical trials
focused on the impact of various immunosuppression
strategies on long-term renal function.111
The following strategies aim to halt the progression of
renal impairment or reverse it. This is not meant to be
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an exhaustive literature review but rather is meant to
provide supporting evidence for several acceptable ap-
proaches to the management of post–liver transplant
renal impairment.
REDUCTION OR COMPLETE WITHDRAWAL
OF CNIS
Several studies have looked at a reduction in the
overall dose and subsequent trough levels of CNIs;
others have attempted the complete withdrawal of
CNIs in an attempt to intervene in those patients with
established renal impairment. CNI reduction has
been accomplished with the addition of adjuvant
agents such as MMF and azathioprine.114,115 The few
CNI withdrawal studies have placed patients on MMF
monotherapy.114
Pageaux et al.116 performed a prospective, random-
ized study in patients with established chronic renal
impairment (serum creatinine  140 mol/L). One
study arm had their CNI dose reduced by more than
50% of the initial dose with the addition of MMF (2-3
g/day), and the other study arm maintained CNI mono-
therapy without MMF (however, the patients were al-
lowed to have a maximum CNI dose reduction of 25%).
There was a significant reduction in serum creatinine at
1 year (171 versus143 mol/L) and an improvement in
creatinine clearance favoring the dose-reduced group,
without any risk for rejection. This controlled study was
able to show that in recipients with established renal
impairment years after liver transplantation, the intro-
duction of MMF combined with a significant reduction
of the baseline CNI dose (50%) leads to a significant
improvement in GFR. Additionally, this study reveals
that there is a strong reversible component of renal
impairment.
We have shown similar results in a consecutive
group of stable post–liver transplant recipients on
CNI monotherapy who were evaluated longitudinally
with an accurate, “measured” GFR after a protocol of
CNI reduction to 75% of the baseline with the addi-
tion of MMF.117 This strategy led to substantial im-
provement in the measured GFR from a mean base-
line of 59.5 mL/minute to 69.3 mL/minute 1 year
later. Of significant interest, the patients with more
advanced renal impairment (GFR  60 mL/minute)
achieved the most improvement in GFR over time
with this combination of CNI reduction with MMF.
This adds further support to the fact that intervening,
even when advanced renal impairment is present,
can affect overall renal function, allowing us to spec-
ulate that we may be altering the natural history of
this life-threatening complication.
Several other authors have shown similar results,
with reductions of CNI dosing and the addition of MMF
leading to substantial improvements in calculated cre-
atinine clearance, estimated GFR, and measured GFR
with no appreciable increase in the incidence of acute
rejection.114,118-120 There have been only a few reports
of complete withdrawal of CNIs and the addition of MMF
monotherapy, as this strategy has shown not only im-
provements in creatinine clearance but perhaps an un-
desirable increased risk of acute rejection.119,121
CONVERSION TO A NON–CNI-BASED
THERAPY
The expansion of immunosuppressant agents has in-
creased the opportunity for transplant physicians to
tailor therapy to the individual patient. Effective im-
munosuppression with minimal toxicity remains the
challenge; however, we are clearly approaching these
goals. In those recipients with established renal im-
pairment, mTOR inhibitors such as sirolimus have
been used in an attempt to avoid CNI therapy com-
pletely. Sirolimus-based therapies have shown mixed
results in terms of the potential for renal improve-
ment. Watson et al.122 was not able to show any
appreciable change in the calculated GFR 1 year after
converting a cohort of patients from CNI-based ther-
apy to sirolimus. There are indeed many reports of
significant improvements in GFR in cohorts con-
verted from CNI-based therapy to sirolimus mono-
therapy or sirolimus with MMF; unfortunately, sev-
eral of these studies also reveal that adverse events
are relatively common. Side effects such as protein-
uria, hyperlipidemia, and oral ulcers have limited the
widespread use of sirolimus and erase any benefit to
renal function that may exist. Several large-scale
studies with a uniform patient population are in
progress, and early reports do reveal an improvement
in renal function in those randomized to sirolimus
therapy versus CNI-based therapy. There may con-
tinue to be a cost to pay with sirolimus, however,
as more severe rejection episodes are noted in addi-
tion to other adverse effects that affect patient
morbidity.123-127
INITIAL INDUCTION THERAPY WITH THE
DELAYED USE OF CNIS
In an attempt to delay the introduction of CNIs, induc-
tion therapy can be used, particularly in those individ-
uals with abnormal renal function at the time of trans-
plantation. The use of a potent induction therapy
followed by a delayed introduction of CNIs has been
shown to produce improvements in GFR.128 A recent
publication of the first prospective, randomized study
evaluating renal function with induction therapy re-
vealed that only a short delay in CNI introduction (4-10
days), in conjunction with daclizumab and MMF, pre-
served early renal function 1 and 6 months after liver
transplantation without increasing the risk for acute
rejection.129 Others have also shown improvements in
both short-term and long-term calculated GFR with the
use of the induction agents daclizumab and antithymo-
cyte globulin in combination with MMF.130
SUMMARY
Chronic renal impairment is exceedingly common af-
ter liver transplantation. Several strategies have been
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employed to reduce or avoid CNIs with a goal of re-
ducing CNI nephrotoxicity. Significant reductions or
withdrawal of CNIs with the addition of adjuvant
agents such as MMF have proven effective in improv-
ing estimated and measured GFR. Several studies
support the idea that significant reductions in the
CNI dose with the addition of MMF can lead to im-
proved renal function without added toxicity or costs.
However, the complete withdrawal of CNIs seems to
lead to higher rejection rates and should be avoided.
The substitution or conversion from CNI-based ther-
apy to novel mTOR agents such as sirolimus has
shown an inconsistent benefit in renal function yet a
clear increase in various adverse events, so this strat-
egy is limited to a select group of patients. Strategies
that employ the use of induction agents at the time of
transplantation seem to halt the early onset of renal
dysfunction. Thus, induction therapy may be appro-
priate for recipients with preexisting renal impair-
ment. In these patients, under the cover of a potent
induction agent, corticosteroids, and MMF, one can
delay the use of CNIs with the proven benefit of a
reduction in short-term renal impairment.
The optimum immunosuppressive strategy for im-
proving the long-term costs and complications associ-
ated with renal impairment remains unclear; however,
until more prospective, randomized studies are per-
formed, an individualized approach to immunosup-
pression is recommended in which ideally renal func-
tion remains a critical variable.
Renal Protection Strategies: Lessons from Renal
Transplantation
Marcelo Cantarovich
Renal transplantation is the treatment of choice for
patients experiencing end-stage renal disease. Over the
past 2 decades, we have observed a reduction in the
incidence of acute rejection from 30% to 55% to
15%.101,131-133 However, long-term graft survival has
not improved. The main causes of graft loss include
death with a functioning graft134 and chronic allograft
nephropathy, which is presently known as interstitial
fibrosis and chronic atrophy not otherwise specified
(IF/TA).135 The causes of IF/TA are multifactorial and
include immunological and nonimmunological fac-
tors.136-139 The currently used calcineurin inhibitors
(CNIs), cyclosporine A (CsA) and tacrolimus (Tac), have
been associated with the development of IF/TA. Proto-
col biopsies showed a 50% incidence of severe chronic
changes in patients receiving CsA at 10 years’ follow-
up.140 More recently, a progression of chronic changes
was observed in 6-month protocol biopsies in 20.5%
and 38% of patients treated with Tac.141
The present review analyzes current immunosuppres-
sive strategies used to either treat renal transplant pa-
tients with renal dysfunction or prevent its development.
Some of the studies have addressed the development
and/or progression of IF/TA. Nonimmunosuppressive
strategies such as the use of pulsatile machine perfusion
for kidney preservation, the use of angiotensin-converting
enzyme inhibitors and/or angiotensin receptor blockers,
the treatment of hypercholesterolemia, prophylaxis for
cytomegalovirus infection, and the prevention and treat-
ment of polyomavirus nephropathy and cigarette use
are not discussed in the present review. The following
strategies are summarized: avoidance of nephrotoxic
combinations, CNI avoidance, use of low-dose CNIs,
and early and late CNI withdrawal.
AVOID NEPHROTOXIC COMBINATIONS
Meier-Kriesche et al.142 described decreased graft sur-
vival in patients receiving a combination of either CsA
or Tac and rapamycin (Rapa). The authors analyzed
23,016 patients from the Scientific Registry of Trans-
plant Recipients between January 1998 and July 2003.
Patients receiving CsA and Rapa had decreased graft
survival at 4 years post-transplant in comparison with
patients receiving CsA and mycophenolate mofetil
(MMF; 74.6% versus 79.3%, P  0.002) as well as de-
creased death-censored graft survival (83.7% versus
87.2%, P  0.003). The same authors analyzed 44,915
patients on Tac-based immunosuppression from the
Scientific Registry of Transplant Recipients between
2000 and 2004. The combination of Tac with Rapa
resulted in decreased death-censored graft survival at 3
years in patients on Tac and Rapa in comparison with
patients on Tac and MMF (83.6% versus 90.4%, P 
0.001) as well as decreased graft survival in recipients
of expanded criteria donor organs (74.5% versus
57.5%, P  0.001).143
USE OF LOW-DOSE CNIS
In a randomized controlled trial including 1645 pa-
tients (the SYMPHONY trial), Ekberg et al.101 compared
low-dose Tac (trough level  3-7 ng/mL), low-dose Rapa
(trough level  4-8 ng/mL), and low-dose CsA (trough
level  50-100 ng/mL) in combination with dacli-
zumab, MMF, and corticosteroids and standard-dose
CsA (trough level  150-250 ng/mL) in combination
with MMF and corticosteroids. At 1 year, the low-dose
Tac group had a lower rate of acute rejection [12.3%
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versus 24% (low-dose CsA), 37.2% (low-dose Rapa), and
25.8% (standard-dose CsA)] and a higher glomerular
filtration rate (GFR; 69.6 versus 65.3, 64.4, and 63.5
mL/minute, respectively) in comparison with the other
treatment groups.
CNI AVOIDANCE
Flechner et al.144 compared Rapa (n  31) and CsA (n 
30) in combination with basiliximab induction, pred-
nisone, and MMF. There was no significant difference in
the incidence of acute rejection in Rapa-treated patients
(6.4%) and CsA-treated patients (16.6%). The 5-year
death-censored graft survival rate was higher with Rapa
versus CsA (96.4% versus 76.7%, P  0.02). Moreover,
patients on Rapa had a higher estimated GFR.145
In a randomized controlled trial, Larson et al.100 com-
pared Tac to Rapa in combination with prednisone and
MMF in 165 renal transplant patients. The incidence of
acute rejection was 10% in patients receiving Tac and
13% in those treated with Rapa. At 1 year post-trans-
plant, protocol biopsies showed no difference in inter-
stitial fibrosis, tubular atrophy, or glomerulopathy.
However, chronic vascular lesions were more frequent
with Tac versus Rapa (43% versus 26%, P  0.03). The
iothalamate GFR was higher with Rapa at 1 month, but
there was no significant difference at 12 and 24 months
post-transplant. Asberg et al.146 compared daclizumab
induction (5 doses), MMF (1.5 g twice daily), and pred-
nisone to CsA, MMF (1.0 g twice daily), and prednisone
in 54 low-risk renal transplant recipients (0% panel
reactive antibodies and human leukocyte antigen DR–
identical). The incidence of acute rejection was higher
in the CsA avoidance group (70.4% versus 29.6%, P 
0.006). However, graft survival and the radionuclide
GFR were similar at the 12-month follow-up.
In a single-arm, multicenter study, Vincenti et al.147
evaluated the combination of daclizumab (5 doses),
MMF (1.5 g twice daily for 6 months followed by 1.0 g
twice daily), and prednisone in 98 renal transplant re-
cipients with low immunological risk. The incidence of
acute rejection was 48%. Acute rejection episodes were
reversible. CNIs were initiated in 62% of the patients.
In a prospective, randomized controlled trial (n 
218), Vincenti et al.148 compared costimulatory path-
way blockade with belatacept (intensive and less inten-
sive groups) and CsA. All the patients received pred-
nisone and MMF. The incidence of acute rejection did
not differ in the 3 treatment groups (7%, 6%, and 8%).
However, patients receiving belatacept (intensive and
less intensive groups) had a higher GFR (66 and 62
mL/minute/1.73 m2) than CsA-treated patients (53.5
mL/minute/1.73 m2). Moreover, patients receiving be-
latacept experienced a lower incidence of chronic allo-
graft nephropathy at 1 year (29% and 20% versus 44%
in CsA-treated patients).
EARLY CNI WITHDRAWAL
Kreis et al.99 studied 525 renal transplant patients on
Rapa, CsA, and prednisone. At 3 months, 430 pa-
tients were randomized to continue on the same reg-
imen or discontinue CsA and continue on Rapa
(trough levels were increased from 5 to 20-30 ng/mL)
in combination with prednisone. There was no differ-
ence in 3-year patient survival (94.4% versus 96.3%)
or graft survival (91.2% versus 93.5%). The incidence
of acute rejection was 9.3% versus 10.2% pre-ran-
domization and 5.6% versus 10.2% post-randomiza-
tion in CsA-treated and Rapa-treated patients, re-
spectively. At the 3-year follow-up, the GFR was 65
mL/minute in Rapa-treated patients versus 55 mL/
minute in CsA-treated patients. Conversion to Rapa
resulted in an improvement in renal function in pa-
tients with a GFR  67 mL/minute versus a decline in
patients on CsA.
Ekberg et al.149 (the CAESAR study) randomized 536
patients into 3 groups:
Group 1: Daclizumab, MMF, steroids, and low-dose
CsA (trough level  50-100 ng/mL), with weaning be-
gun in month 4 and discontinuation by month 6.
Group 2: Daclizumab, MMF, steroids, and low-dose
CsA.
Group 3: MMF, steroids and standard-dose CsA.
The incidence of acute rejection was significantly
higher in group 1 (38%) versus group 2 (25.4%, P 
0.027) and group 3 (27.5%, P  0.04).
Flechner et al.150 (the Orion trial) randomized 451
renal transplant patients into 3 groups:
Group 1: Rapa (8-15 ng/mL and then 12-20 ng/mL
after week 13) and Tac (6-15 ng/mL), with discontinu-
ation at 13 weeks.
Group 2: Rapa (10-15 ng/mL until week 26 and then
8-15 ng/mL) and MMF.
Group 3: Tac (8-15 ng/mL until week 26 and then
5-15 ng/mL) and MMF.
All the patients received corticosteroids and dacli-
zumab. The incidence of acute rejection was signifi-
cantly higher (P  0.01) in group 2 (28.3%) versus group
1 (14.5%) and group 3 (9.4%). This resulted in an early
termination of group 2.
Pearson et al.151 (the Spare the Nephron trial) ran-
domized 298 patients between 30 and 180 days post–
renal transplant to either continue on a CNI (81% of
the patients were on Tac) or convert from a CNI to
Rapa (trough level  5-10 ng/mL) in combination
with MMF. Induction therapy and steroid use were
based on center practice. The incidence of acute re-
jection was 7% in all groups. One year after random-
ization, the GFR increased by 27.9% in patients con-
verted to Rapa versus 11% in those who remained on
a CNI (P  0.052) and 6.1% in those who remained on
Tac (P  0.02). There was a higher incidence of pe-
ripheral edema, oral ulcers, back pain, hypertension,
hyperlipidemia, hypokalemia, and proteinuria in pa-
tients on Rapa.
LATE CNI WITHDRAWAL
Birnbaum et al.152 reported a systematic review of 12
randomized controlled trials including 635 patients
with chronic allograft dysfunction or chronic allograft
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nephropathy (the term used before IF/TA). All patients
were on a CNI, most often CsA, and were 6 months
post-transplant at the time of randomization. The pa-
tients were converted to MMF, Tac or Rapa, or azathio-
prine, MMF or Rapa was added to their immunosup-
pressive regimen. The follow-up time ranged from 6 to
36 months. The results suggested that conversion from
a CNI to MMF or Rapa may be beneficial with respect to
renal function. Moreover, one trial showed a decreased
incidence of chronic lesions in patients on MMF/Rapa
compared to patients who continued on a CNI.153 The
incidence of graft loss ranged from 0% to 19%. On the
other hand, the incidence of side effects was reported to
be up to 50% with MMF and up to 68% with Rapa, and
these side effects led to MMF or Rapa withdrawal in 0%
to 24% of patients.152
CONCLUSIONS
The combination of a CNI and Rapa is associated with
inferior long-term graft survival in comparison with a
CNI and MMF.142,143 The use of low Tac trough levels
(3-7 ng/mL) in combination with MMF and prednisone
results in a lower acute rejection rate and a higher GFR
in comparison with standard-dose and low-dose CsA
and low-dose Rapa.101
There are controversial results regarding the inci-
dence of acute rejection in CNI avoidance protocols us-
ing MMF and Rapa and anti-CD25 monoclonal anti-
body induction.100,144,146,147 Strategies using Rapa,
MMF, and prednisone as well as belatacept, MMF, and
prednisone have resulted in a lower incidence of
chronic lesions without increasing acute rejection rates
versus CNIs.100,145,148
Early CNI discontinuation has resulted in a vari-
able incidence of acute rejection. A higher acute re-
jection rate has been observed after the discontinua-
tion of CsA,99,149 whereas no difference has been
observed in other trials in which a majority of the
patients discontinued Tac.150,151 However, acute re-
jection does not seem to influence graft survival dur-
ing the early follow-up. Conversion to Rapa resulted
in an improvement in renal function in patients with
a GFR  67 mL/minute versus a decline in patients
on CsA.99 The drawback remains the higher inci-
dence of side effects in patients receiving the MMF/
Rapa combination.151 The late conversion from a CNI
to MMF and/or Rapa results in an improvement in
renal function versus continuation on a CNI, a re-
duced-dose CNI, or a reduced-dose CNI and Rapa.152
There is a potential for decreased progression of IF/
TA,153 and the incidence of graft loss ranges from 0%
to 19%.152 There is an increased incidence of side
effects secondary to MMF and Rapa that need to be
balanced with the benefits of this combination. Fu-
ture strategies should focus on the optimization of
the presently used renal protective strategies and the
development of new immunosuppressive combina-
tions with a lower side-effect profile.
New Immunosuppressive Agents and New
Protocols: Impact on Renal Function in Liver
Transplantation
James D. Eason
Many new immunosuppressive agents are being tested
in investigative trials trying to decrease the reliance on
calcineurin inhibitors (CNIs) in liver transplantation.
One of the primary incentives for developing these new
agents is to decrease the impact of immunosuppression
on renal dysfunction following transplantation. There is
limited experience with these new agents in liver trans-
plantation. This report summarizes new immunosup-
pressive agents under investigation and their possible
role in preserving renal function in liver transplanta-
tion. Experience using rabbit antithymocyte globulin
(RATG) in a CNI-sparing protocol is summarized as
well.
Current clinical trials of the effects of immunosup-
pression on renal function in liver transplantation from
ClinicalTrials.gov154 are as follows:
1. AEB071: pharmacokinetics with tacrolimus (Eu-
rope).
2. Everolimus with basiliximab versus cyclosporine
(Europe).
3. Everolimus: tacrolimus withdrawal (United States).
4. Belatacept versus tacrolimus (United States).
5. Thymoglobulin: delayed tacrolimus (Nebraska).
6. Sirolimus with mycophenolate mofetil (MMF) and
anti-CD25 induction.
7. Spare the Nephron: sirolimus with MMF versus CNI
with MMF.
New agents under investigation in transplantation
fall into the 4 main categories listed here:
1. Costimulatory blockade: belatacept,155-157 efali-
zumab,156-158 and alefacept.156,157,159
2. Inhibitors of proliferation signals: everolimus.160
3. Janus kinase 3 (JAK3) inhibitors: CP690550 9.156,157
4. Protein kinase C inhibitor: AEB071.156,157
5. Inhibitors of nucleotide synthesis: FK778.156,157,160
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6. Inhibitors of lymphocyte trafficking: fingolimod
(FTY-720).156,157
7. Potentially less nephrotoxic CNIs: ISA-247.
Belatacept and alefacept are examples of costimu-
latory blocking agents. Belatacept (LEA29Y) is a sec-
ond-generation cytotoxic T lymphocyte antigen 4
(CTLA4)–immunoglobulin that blocks the CD28/
CTLA4-CD80/CD86 binding interactions. Blockade
of this interaction inhibits T cell proliferation. Belata-
cept has been investigated in a phase II kidney trans-
plantation trial against cyclosporine. This trial con-
sisted of belatacept injections every 2 weeks for 1
year. There was an improvement in the glomerular
filtration rate in the belatacept-treated group over
cyclosporine, but there was no difference in biopsy-
proven acute rejection.155-157 Belatacept is now being
investigated in a phase II clinical trial in liver trans-
plantation.
Efalizumab is a humanized monoclonal antibody to
CD11a that interferes with lymphocyte function–as-
sociated molecule 1/intercellular cell adhesion mol-
ecule interaction. Efalizumab has been investigated
in phase II and III clinical trials in renal transplanta-
tion in conjunction with full-dose or half-dose cyclo-
sporine, MMF, and steroids. The efalizumab arms
had decreased rejection and no identified nephrotox-
icity.156-158 There are no liver transplant data at this
time.
Everolimus is a mammalian target of rapamycin in-
hibitor that inhibits proliferation signals. It has been
used successfully in CNI conversion trials in liver trans-
plantation in Europe. Conversion from a CNI to everoli-
mus was feasible in 75% of the cases and was associ-
ated with improvements in renal function for patients
with higher baseline calculated creatinine clearance. It
is currently under investigation in the United States in
a tacrolimus-withdrawal trial.160
Alefacept is an anti-CD2 antibody consisting of a lym-
phocyte function–associated molecule 3/immunoglob-
ulin G fusion protein. Alefacept blocks CD2, causing
apoptosis of effector memory cells. It has been approved
for psoriasis and has no known nephrotoxicity. There
are no transplant data on alefacept at this time, except
for the treatment of graft-versus-host disease in bone
marrow transplantation.156,157,159
JAK3 inhibitors block signal 3 of the immune re-
sponse and are lymphoid-specific. These agents inter-
fere with JAK3-dependent interleukin 2 (IL2) prolifera-
tion of T cells. CP690550 is a JAK3 inhibitor that has
been used in phase II trials comparing JAK3 to tacroli-
mus with IL2 receptor antibody, MMF, and steroids in
renal transplants. There was no difference in biopsy-
proven acute rejection or the estimated glomerular fil-
tration rate at 6 months.156,157 There are other JAK3
inhibitors in early trials.
AEB-071 is a protein kinase C inhibitor with inhibi-
tion of both lymphocyte proliferation and IL2 messen-
ger RNA expression. This inhibition abolishes the pro-
duction of several cytokines by activated human T cells.
AEB-071 has been used in CNI-free protocols for kid-
neys, but these trials were stopped because of an in-
creased incidence of acute rejection in the AEB-071
arm. There is an ongoing CNI-free kidney trial as well as
pharmacokinetic trials in liver transplantation in Eu-
rope. AEB-071 has no known nephrotoxicity.
FTY-720 is an immunomodulator, that is, an agonist
of sphingosine 1–phosphate receptor 1 on thymocytes
and lymphocytes that regulates egress from the thymus
and peripheral lymphoid organs. FTY-720 causes inter-
nalization of the receptor, rendering cells unresponsive
to signals to egress from lymphoid organs. Clinical tri-
als of FTY-720 in kidney transplantation with reduced-
dose cyclosporine A demonstrated increased acute re-
jection macular edema in some subjects, and this
caused further transplant studies to be discontin-
ued.156,157 There was no direct nephrotoxicity. FTY-
720 is currently being evaluated for multiple sclerosis.
ISA-247 is a novel, potent CNI. In interim results of a
phase 2b study in kidney transplant recipients (n 
116), ISA-247 was associated with a frequency of acute
cellular rejection that is similar to that observed in the
control, tacrolimus-based arm.
In an ongoing single-center study of RATG induction as
a CNI-sparing protocol in steroid-free liver transplanta-
tion,161 315 patients were induced with RATG (1.5 mg/
kg) in the anhepatic phase and on posttransplant day 2
for a total of 3 mg/kg. Maintenance therapy with MMF
was started on day 1 and continued for 3 months. Tacroli-
mus was delayed a minimum of 3 days or when serum
creatinine fell below 2 mg/dL. Primary sirolimus was ini-
tiated in 35 patients with serum creatinine  2.5 by day
14. Mean tacrolimus levels were 7.2, 7.4, 7.1, and 5.8 at 1
month, 3 months, 6 months, and 1 year, respectively. The
serum creatinine level and estimated glomerular filtration
rate assessed in 180 patients who were at least 1 year out
from transplant showed a slight worsening at 1 month
post-transplant with a slow and steady improvement at 6
months and 1 year post-transplant (Figs. 8 and 9). Patient
survival and graft survival at 1 year were 90% and 87%,
respectively, with a 10% incidence of steroid-requiring
rejection. Conclusions at this time from this experience
are that tacrolimus can be safely delayed up to 14 days
with RATG induction in the absence of steroids with ex-
cellent patient and graft survival and a low incidence of
rejection. Delaying and decreasing tacrolimus dosing may
Figure 8. Serum creatinine in rabbit antithymocyte globulin
induction with calcineurin inhibitor delay and reduction.
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provide long-term protection against further declines in
renal function.
SUMMARY AND CONCLUSIONS
Although there are many new agents on the horizon,
several agents that were thought to be promising have
been discontinued because of inferior results or prohib-
itive side effects. The most promising new strategies are
costimulatory blockade with belatacept, alefacept, or
efalizumab and JAK3 and protein kinase C inhibition.
Antibody induction with CNI delay and even avoidance
shows promising early results.
Intraoperative Renal Protection: Anesthesia
Approaches
Michael A.E. Ramsay and Juan Carlos Garcı́a-Valdecasas
The strategy for intraoperative renal protection during
liver transplantation is the prevention of injury or, in
many patients, further injury to the kidney. Renal isch-
emia, inflammation, and exposure to nephrotoxins are
the main reasons that renal dysfunction or failure can
develop during liver transplantation.2 Liver recipients
are at increased risk in the intraoperative period for
renal deterioration because they frequently present
with preexisting renal dysfunction, often as a result of
hepatorenal syndrome. Intraoperatively, severe hemo-
dynamic and volume changes occur, and at reperfusion
of the liver graft, the new organ, the kidneys, and other
major organs are exposed to inflammatory cytokines.
The vascular endothelium is particularly at risk during
the ischemia/reperfusion (I/R) period.162 The glo-
meruli are an extension of this vascular endothelium.
The exposure to potential nephrotoxic drugs may oc-
cur intraoperatively with the administration of agents
such as vancomycin and calcineurin immunosup-
pressants. Blood flow to the kidneys is autoregulated
to maintain a stable glomerular filtration rate with an
arterial pressure of approximately 80 to 160 mm Hg.
This autoregulation maintains fluid and salt balance
and preserves the glomerular structure. Azotemia
and oliguria can represent specific diseases, but they
may also be manifestations of a normal response of
the kidneys to volume depletion or a reduction in
renal blood flow.
Hemorrhaging and the need for large-volume red
blood cell and plasma transfusions are detrimental to
renal perfusion and contribute to the risk of postoper-
ative renal failure. Measures during the operation
should be aimed at avoiding hemorrhaging and, by do-
ing so, reducing the risk of renal compromise. As gen-
eral principles, maintenance of adequate blood pres-
sure (tissue perfusion) and avoiding the need for a
massive transfusion are desirable in liver transplanta-
tion, as they are in all operations.163
During the procedure, the aim is to maintain the
coagulation profile, which will enhance hemostasis,
and minimize the requirement for transfusion of blood
products, including plasma and red blood cells.164,165
American Society of Anesthesiologists guidelines sug-
gest that the threshold for a red blood cell transfusion is
a hemoglobin level within 60 to 100 g/L, the threshold
for plasma is an international normalized ratio greater
than 1.5, and the threshold for a platelet transfusion is
a platelet count less than 50  109/L.166 By a combi-
nation of isovolemic hemodilution and maintenance of
a low central venous pressure (keeping the patient
“dry”), Massicotte et al.167 showed that the need for a
red blood cell transfusion during the procedure is sig-
nificantly reduced, and this consequently decreases the
number of postoperative complications, including renal
failure.168
Using a similar approach that also preserves the vena
cava (piggyback technique) and uses a portocaval
shunt during the anhepatic phase, we can significantly
reduce blood product requirements while maintaining
adequate diuresis168 (Table 3). This technique also em-
ploys a continuous infusion of norepinephrine to main-
tain a mean arterial pressure above 65 mm Hg.
Venovenous bypass, the piggyback technique, and
temporary portocaval shunts share the same objective
of maintaining hemodynamic stability during the anhe-
patic period. A prospective, randomized trial of veno-
venous bypass showed that, although renal function
was adequately preserved during the anhepatic phase,
the effect did not last for more than 24 hours.169 The
beneficial effect (as measured by inulin clearance, uri-
nary 2-microglobulin, and N-acetyl--D-glusamini-
dase) was evident only during the operation. It has been
shown that the piggyback technique does not compro-
Figure 9. Estimated glomerular filtration rate in rabbit anti-
thymocyte globulin induction with calcineurin inhibitor delay
and reduction.
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mise renal outflow at any time, maintaining normal
kidney function.170 The anastomosis of the donor liver
to the vena cava is performed at the junction of the 3
hepatic veins, with care taken to avoid compromising
vena cava flow.171,172 It has been argued that preserv-
ing the vena cava is the most “physiological” method of
removing the diseased liver. A massive transfusion of
fluid to maintain hemodynamic stability is avoided dur-
ing the anhepatic phase.
In a recent randomized trial of temporary portocaval
shunting during the anhepatic phase, Figueras et al.173
showed that the technique can decrease blood transfu-
sion requirements, but there was no significant im-
provement in postoperative renal function. The use of
apronitin to reduce bleeding has been common, but a
recent report of diminished survival and worse serum
creatinine levels in cardiac surgery patients who re-
ceived aprotinin has limited its use in liver transplan-
tation.174
Pharmacological agents are used in combination with
volume replacement to maintain a mean arterial pres-
sure above 65 mm Hg.175 Norepinephrine appears to be
the vasopressor of choice.176,177 The use of loop diuret-
ics and “renal-dose” dopamine, although common, does
not prevent renal injury.178-183 Pretransplant use of
vasoconstrictors, such as terlipressin, has demon-
strated some promise in the management of hepatore-
nal syndrome, but to date, no data exist about the
intraoperative use of vasopressin analogues.184
Fenoldopam has been demonstrated to reduce the need
for renal replacement therapy in cardiovascular sur-
gery, but its efficacy in the liver transplant recipient is
still controversial.185-189 Abdominal compartment syn-
drome, causing compression on the kidneys, can be a
significant cause of renal dysfunction following liver
transplantation.190
The vascular endothelium is activated by both the
ischemia and reperfusion stages of liver transplanta-
tion. This results in the activation of polymorph neu-
trophils and platelets causing adhesion to the endothe-
lium, creating a proinflammatory and prothrombotic
surface and a loss of local vasoactive mechanisms. This
process is facilitated by increased permeability of the
endothelium, cell adhesion molecules, and inflamma-
tory cytokines. The endothelial dysfunction is further
enhanced by a depletion of nitric oxide resulting in a
vasoconstrictive state. Oxidative stress results in an
increase in reactive oxygen species that include super-
oxide, hydrogen peroxide, and hydroxyl ions. These free
radicals also cause extensive cellular damage. The cy-
toprotective effects of antioxidants are inactivated by
the massive oxidant load caused by the I/R syndrome.
The vascular dysfunction caused by this cascade of
events may result in a systemic inflammatory response
causing multiorgan dysfunction, including renal fail-
ure.
Many therapeutic approaches have been tried in an
effort to reduce the injuries caused by reperfusion. They
include the use of free-radical scavengers, vasodilators
such as inhaled nitric oxide, prostaglandin E1, and
various antioxidants. Ischemic preconditioning is being
investigated as a method of preventing I/R-induced in-
jury. Because oxidative stress and associated inflam-
mation are potential mechanisms for renal injury dur-
ing surgery, strategies to reduce inflammation include
the administration of N-acetyl cysteine. N-Acetyl cys-
teine, a scavenger of oxygen free radicals, potentially
can stimulate endothelium-derived relaxing factor,
thereby improving microvascular blood flow. The data
for perioperative renal protection are not yet convinc-
ing, but it warrants further trials.191-194 In a small
human study, inhaled nitric oxide at 80 ppm intraop-
eratively was demonstrated to attenuate the I/R injury
and improve liver graft function.195 This should have a
positive downstream effect on the other major organs,
including the kidneys, and warrants further study.
TABLE 3. Analysis Comparing 2006 and 2007 with Respect to Blood Cell Component Requirements and Renal
Function
2006 (n  69) 2007 (n  78) P
Plasma-Lyte (mL) 2328 	 941 1887 	 632 0.001
FFP (mL) 1884 	 1910 1240 	 1014 0.01
RBC (U) 5.6 	 7.2 3.3 	 3.1 0.014
Diuresis 1406 	 895 1056 	 622 0.006
Balance (mL) 
785 	 2309 
812 	 1296 NS
Final Hb (g/L) 94 	 9 97 	 2 NS
Cr (baseline) (mg/dL) 0.99 	 0.3 0.91 	 0.3 NS
Cr (24 hours) (mg/dL) 0.99 	 0.4 0.95 	 0.4 NS
NOTE: Significant differences were found with respect to blood products and Plasma-Lyte, whereas similar renal function was
maintained. This table is reprinted with permission from Beltran et al.168
Abbreviations: Cr, creatinine; FFP, fresh frozen plasma; Hb, hemoglobin; NS, not significant; RBC, red blood cell.
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Summary of Posttransplant Strategies
James Neuberger
The improved outcomes after liver transplantation over
the last 3 decades are due primarily to a reduction in
early mortality and graft loss in the first 6 to 12
months.196 The lack of improvement in patient and
graft survival over the longer term is likely due to a
combination of many factors, some of which are asso-
ciated with the need for chronic immunosuppression.
There are several approaches to minimizing cal-
cineurin inhibitor (CNI) nephrotoxicity, and the first is
to prevent and/or treat other causes of nephrotoxicity
such as hypertension and diabetes mellitus. Unneces-
sary damage to the kidneys should be avoided by lim-
iting the use of nephrotoxic agents such as nonsteroidal
anti-inflammatory drugs.
Deliberate modifications in the use of CNIs to avoid
nephrotoxicity are common. They include avoiding
them entirely, delaying their introduction, and mini-
mizing their dose. Several studies have shown that late
CNI-associated nephrotoxicity is predicted by pretrans-
plant renal function and the level and dose of the CNI in
the first 6 to 12 months post-transplant.19,93 Thus, the
risk of renal failure is determined, at least in part, by
early events; therefore, especially in those at risk, strat-
egies should be aimed at minimizing high concentra-
tions of CNIs in the first year. However, the use of both
cyclosporine and tacrolimus has been associated with
better graft and patient survival,197 so most clinicians
will still use these agents. Sirolimus is usually not used
in the first 6 months because of its impact on wound
healing and possible thrombotic tendency, which may
result in graft loss from hepatic artery thrombosis. One
approach is to use induction therapy (such as interleu-
kin 2 receptor blocking, campath-1, or thymoglobulin)
with corticosteroids and an antimetabolite such as my-
cophenolate.
There are now a few studies that have used delayed
introduction of CNIs (until days 5-7) and shown that, at
least in the short term, this approach is associated with
less nephrotoxicity at 1 year.129,198 Whether this will be
extrapolated to less renal failure in the longer term is
uncertain, and whether this immunosuppression regi-
men will be associated with other problems, such as
more aggressive hepatitis C disease, again remains to
be shown.
It is popular to aim for lower blood levels of CNIs,
usually in conjunction with the use of other nonneph-
rotoxic immunosuppressants. The target levels of CNIs
are derived from both the experience of renal transplan-
tation and clinical experience. However, there is no
strong reason to believe that blood concentrations of
either tacrolimus or cyclosporine will fully reflect the
completeness of the reduction of the antigraft immune
response or that nephrotoxicity may not develop at a
concentration similar to (or indeed below) that which is
immune-effective. Thus, one strategy in the develop-
ment of renal impairment will be to reduce the CNI dose
and monitor the recipient for signs of early rejection.
The reduction in the CNI dose can be done either with
monotherapy or with the addition of other immunosup-
pressive agents, such as mycophenolate and/or corti-
costeroids.
When patients manifest evidence of CNI nephrotoxic-
ity, the clinician has several options, including reduc-
ing the CNI without altering other immunosuppressive
drugs; reducing the CNI with an increase in or addition
of other agents; and switching to alternative non-CNI
regimens, such as mycophenolate monotherapy, myco-
phenolate with steroids, steroids and azathioprine, or
sirolimus. Mycophenolate monotherapy has been asso-
ciated with acute rejection, ductopenic rejection, and
graft loss.199 Switching to sirolimus may be helpful in
selected cases, but the agent itself is associated with
other toxicities and should be avoided when there is
significant proteinuria. Improvement in renal function
does not always occur.200 There are no strong data to
tell the clinician at what level of renal impairment
switching should start or above what level of impair-
ment the change is futile.
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Immunosuppression Withdrawal: A Strategy to
Improve the Renal Function of Liver Transplant
Recipients?
Sandy Feng
To a tremendous degree, the everyday success of liver
transplantation has been attributed to the emergence
of calcineurin inhibitors as the primary axis of immu-
nosuppression. However, the main toxicity of cal-
cineurin inhibitors is well known to be nephrotoxicity.
For adult liver transplant recipients, the cumulative
incidence of chronic renal failure has been reported to
be 8.0%  0.1% at 1 year, 13.9%  0.2% at 3 years, and
18.1%  0.2% at 5 years after liver transplantation.2 Of
children who are, on average, 7.6  3.4 years after liver
transplantation (range  3-14.6 years), 32% suffer from
renal dysfunction, which is defined as a measured glo-
merular filtration rate of less than 70 mL/minute/1.73
m2.201 Calcineurin inhibitor withdrawal, in the context
of tolerance trials, has obvious implications for renal
function in liver recipients.
Several single-center experiences have demonstrated
that prospective immunosuppression withdrawal can
be successful for both adult and pediatric liver trans-
plant patients.202-213 Table 4 summarizes the pub-
lished experience for adults. Of 316 adult patients for
whom immunosuppression withdrawal was attempted,
57 (18%) were successful; 168 (53%) developed clini-
cally suspected and/or biopsy-proven acute rejection,
and 9 (3%) experienced chronic rejection with 2 result-
ant deaths and 2 patients undergoing retransplanta-
tion. Unfortunately, the subgroups of recipients in
which withdrawal was attempted were often poorly de-
fined and differed from center to center, yielding impre-
cise information concerning the prevalence of func-
tional tolerance either in the overall group or in a well-
defined subset of the adult transplant population. For
pediatric liver transplant recipients, the outcome of im-
munosuppression withdrawal may be better. The Uni-
versity of Pittsburgh has provided updated information
regarding the subset of pediatric liver transplant recip-
ients for whom withdrawal has been attempted. Of 64
children, 22 (34%) appeared to be functionally tolerant,
9 (14%) experienced acute rejection, and none experi-
enced chronic rejection203,204 (G. Mazariegos, personal
communication, 2009). The Kyoto group initially re-
ported on a cohort of 63 pediatric liver transplant re-
cipients206,207; 24 (38%) were successfully withdrawn
from immunosuppression for a median of 23.5 months
(range  3-69 months), whereas 16 (25%) experienced
acute rejection, and a single patient developed chronic
rejection, which was successfully managed with triple
immunosuppression (corticosteroids, tacrolimus, and
mycophenolate mofetil). More recently, however, the
same group has reported that 87 of 581 children or 15%
of their entire cohort of pediatric liver transplant recip-
ients have been withdrawn from all maintenance im-
munosuppression.214 Detailed information on how
many children have attempted, are undergoing, or have
failed withdrawal is unknown.
Although the benefit of immunosuppression with-
drawal may be deeply intuitive, few withdrawal experi-
ences have yielded proof as their focus has, heretofore,
primarily been to document success and failure rates.
Thus far, the only published reports examining poten-
tial benefits have come from Tor Vergata (Italy) and
have been based on the hypothesis that restoration of










1994 Mayo3 12 0 6 3 (2 deaths)
1997 Pittsburgh4,5 95 18 (19%) 21 3
1998 King’s6 18 5 (17%) 13 (4 bx pr) 1 (1 retx)
2003 Spain9 9 3 (33%) 6 (2 bx pr) 0
2005 Miamai10 104 20 (19%) 70 (30 bx pr) 2 (1 retx)
2005 Ochsner11 18 1 (6%) 11 0
2006 Tor Vergata12 34 8 (23%) 26 0
2007 Ontario13 26 2 (8%) 15 0
Total 316 57 (18%) 168 (53%) 9 (3%)
Abbreviations: bx pr, biopsy-proven; retx, retransplanted.
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immune competence might favorably affect posttrans-
plant hepatitis C virus (HCV) outcomes.211 Of the 34
enrolled patients, all on cyclosporine monotherapy, 8
succeeded in withdrawing from and remaining off all
immunosuppression. Initially, they reported that com-
plete withdrawal stabilized the progression of post-
transplant HCV, but longer follow-up, at 78 months
after withdrawal, appeared to erode this advan-
tage.211,215 Of the 8 tolerant recipients, 1 died of severe
HCV recurrence 6 years after withdrawal, but 7 re-
mained off immunosuppression without any evidence
of rejection. Four of 26 intolerant patients died: 2 of
HCV recurrence, 1 of lung cancer, and 1 of acute myo-
cardial infarction. Liver graft pathology was comparable
between the tolerant and intolerant recipients for
necroinflammatory grade, fibrosis stage, and fibrosis
progression rate. Notably, however, none of the tolerant
subgroup developed diabetes, whereas 11 of 22 intoler-
ant recipients required treatment for new onset diabe-
tes mellitus (P  0.03). Moreover, significantly fewer
tolerant patients versus intolerant patients experienced
cardiovascular (0/7 versus 14/22, P  0.01) and infec-
tious (0/7 versus 13/22, P  0.01) morbidity.
Although a report has not yet been published, the
Miami group recently presented at the 2008 American
Transplant Congress long-term follow-up of function-
ally tolerant adult liver transplant recipients.216 Three
years previously, in 2005, they reported on withdraw-
ing immunosuppression from 104 liver transplant re-
cipients, 45 of whom had received donor bone marrow
infusions shortly after transplantation.209 At trial en-
try, all participants were at least 3 years post-trans-
plant, and immunosuppression was withdrawn over 3
years. The functionally tolerant recipients (n  20) were
compared to the intolerant recipients (n  73) with
respect to renal function and de novo malignancy. Tol-
erant patients exhibited lower serum creatinine levels,
and they had fewer cancers during long-term follow-up.
Currently, 1 of the 2 immunosuppression withdrawal
trials for adult liver transplant recipients sponsored by
the Immune Tolerance Network has, as an integral part
of its design and aims, the goal of defining the clinical
benefit of transplantation. The trial (A Phase II Trial to
Assess the Safety of Immunosuppression Withdrawal
in Liver Transplant Recipients; see http://www.
clinicaltrials.gov/ct2/show/NCT00135694) is a pro-
spective, multicenter, open-label randomized trial that
aims to enroll 275 candidates who will undergo liver
transplantation for HCV or nonimmune, nonviral causes.
Participants will receive standard immunosuppression
composed of corticosteroids and a calcineurin inhibitor in
the absence of any induction agents. Between 1 and 2
years after transplant, recipients will be randomized to
withdraw from or stay on maintenance immunosuppres-
sion in a 3 to 1 ratio. Those randomized to weaning will
withdraw from immunosuppression over approximately
56 weeks. Two years following random assignment, the
withdrawal and maintenance immunosuppression
groups will be compared for total immunosuppression
exposure as the primary endpoint and incidence of im-
munosuppression-related complications as one of the
secondary endpoints. Specific complications that will be
assessed include quality of renal function (glomerular fil-
tration rate), severity of hypertension and metabolic ab-
normalities (hypercholesterolemia and diabetes), and
rates of opportunistic infections and secondary malignan-
cies. Therefore, it is very likely that there will soon be data
quantifying clinical benefits associated with attempted
and/or successful immunosuppression withdrawal.
Although immunosuppression withdrawal experi-
ences date back over a decade, only recently have any
glimpses into a profile of functional tolerance begun to
emerge. Two groups, one studying children and the
other studying adults, have reported that functionally
tolerant recipients have increased proportions and ab-
solute numbers of circulating  T cells and a predom-
inance of V1	 cells over V2	 cells.213,214,217,218
One group has also suggested that the expression pat-
terns of as few as 22 genes can accurately predict the
outcome of immunosuppression withdrawal for adult
recipients.217,218 They have suggested that the combi-
nation of peripheral blood cell phenotypic markers and
a characteristic gene expression profile compose a
highly discriminative signature of functional tolerance
for adult liver recipients. In Europe, there is an ongoing
trial (Search for the Immunological Signature of Oper-
ational Tolerance in Liver Transplantation) that aims to
prospectively validate the accuracy of this signature to
predict successful withdrawal (http://clinicaltrials.
gov/ct2/show/NCT00647283). Sponsored by a multi-
national project [Reprogramming the Immune System
for Establishment of Tolerance (RISET)], the trial will
enroll 60 eligible adult liver transplant recipients, sub-
ject them to gradual immunosuppression weaning, and
correlate the immunological and gene expression char-
acteristics with clinical outcome.
The 3 immunosuppression withdrawal trials that are
underway in the United States (2 adult trials and 1
pediatric trial) all include vigorous longitudinal collec-
tion of peripheral blood and liver tissue specimens to
support a parallel search for biomarkers of functional
tolerance. There is substantial hope that these invalu-
able specimens will not only elucidate or confirm a
predictive signature of functional tolerance but also
suggest the mechanisms responsible for establishing
and maintaining the tolerant state.
Clearly, immunosuppression withdrawal as a strat-
egy to mitigate the development of chronic kidney
disease in liver transplant recipients is a concept in
its infancy. The clinical focus of both past and cur-
rent trials has centered on understanding whether
withdrawal is safe, rather than whether it is advan-
tageous. Intuition and common sense suggest that
foregoing lifelong immunosuppression would be
highly desirable and beneficial to patients. This con-
cept, however, remains entirely unproven. The real-
istic horizon of a predictive profile for functional tol-
erance signals the emergence of an entirely new
landscape. The ability to identify liver transplant re-
cipients who are likely to be tolerant of their liver
allograft will tremendously facilitate larger clinical
trials powered to determine the optimal timing, effi-
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cacy, and benefit of immunosuppression withdrawal.
Moreover, a deeper understanding of the tolerance
signature with respect to when it emerges relative to
transplantation and whether it is universal for all
liver transplant recipients will be critical to future
tolerance induction trials that will likely reduce ex-
posure to immunosuppressive regimens centered on
nephrotoxic agents.
CONSENSUS REPORT
Evaluation and Management of Pretransplant
Renal Insufficiency and Criteria for
Simultaneous Liver-Kidney Transplantation
Thomas A. Gonwa and Connie Davis
Every patient undergoing a liver transplant evaluation




3. Urine protein creatinine ratio or 24-hour urine for
protein.
4. Serum sodium.
The group reviewed the value of predictive equations
for the measurement of the glomerular filtration rate
(GFR) and also looked at the results of using cystatin C
to measure GFR. Neither of these methods was recom-
mended. A true GFR measurement was recommended if
possible. It was noted that unpublished data demon-
strated that using a measured GFR to replace creati-
nine in the Model for End-Stage Liver Disease (MELD)
calculations improved the accuracy of MELD to predict
mortality in cirrhosis to the same degree as adding
serum sodium to the MELD calculation.219 However, it
is clear that there is a need to develop standardized
protocols for GFR measurement, particularly when pa-
tients are receiving extra fluid or albumin or have a
Foley catheter. Given the inability of the GFR prediction
equations to accurately predict the true GFR in patients
with cirrhosis,3 greater attention should be paid to de-
veloping a tool to measure GFR that is easy to use and
reproducible. Further renal evaluations should be done
in all patients with a serum creatinine greater than 1
mg/dL, urinalysis showing increased white blood cells,
red blood cells, or casts, or urinalysis showing protein-
uria with increased albuminuria. Further evaluation
should include a measurement of urinary electrolytes,
imaging studies, appropriate immunological tests, ne-
phrology consultation and, potentially, renal biopsy. It
is unclear whether the fractional excretion of sodium or
chloride is consistently useful as it might be dependent
on the recent administration of diuretics. There should
be an anatomic evaluation by sonogram, computed to-
mography scan, or magnetic resonance imaging, with
the choice depending on the clinical setting and the
assessed risks of contrast agents. Any imaging abnor-
mality should prompt a true GFR measurement, pref-
erably one that is non–creatinine-based. If proteinuria
or active urinary sediment is present, appropriate se-
rologies should be obtained, such as anti-neutrophil
cytoplasmic antibodies and anti-nuclear antibodies, as
well as the measurement of cryoglobulins presenting
in hepatitis C–infected patients. Complement levels
should be evaluated; however, low levels may be seen
in severe liver disease and may not be discrimin-
atory.220,221 A measurement of renal blood flow by
Doppler examination is a useful gauge of resistance to
intrarenal blood flow (ie, ischemia) in those regions in
which there is an experienced sonographer. The degree
of sonographically determined resistance has been cor-
related with the development of hepatorenal syn-
drome.222,223 Finally, renal biopsy should be consid-
ered if the urine is abnormal, there is unexplained renal
dysfunction, or there is prolonged renal dysfunction.224
The group discussed the results of using kidney biopsy,
particularly in determining the need for combined kid-
ney-liver transplantation (discussed later).
The group then discussed the criteria for combined
kidney-liver transplantation. The United Network for
Organ Sharing Liver and Kidney Committees are exam-
ining criteria for simultaneous liver-kidney transplan-
tation, and their preliminary proposal served as the
basis for the discussion. The group agreed with the
suggestion that there should be criteria that make the
patient eligible for listing and that patients falling out-
side these criteria should be reviewed by the regional
review board (Table 5).
The first group of patients deemed to be candidates
for simultaneous liver-kidney transplantation includes
those with end-stage renal disease on dialysis. Docu-
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mentation of the dates of the initiation of dialysis and
the cause of end-stage renal disease, as reported on
Centers for Medicare and Medicaid Services form 2728,
would be required for candidacy. The second group
includes patients with chronic kidney disease not on
dialysis but having either a documented GFR of less
than 30 mL/minute by the Modification of Diet in Renal
Disease 6 (MDRD6) equation or a direct measurement
of GFR of less than 30 mL/minute and proteinuria
greater than 3 g per day with a 24-hour protein mea-
surement or a urine protein creatinine ratio greater
than 3. The third group consists of patients with sus-
tained acute renal failure and documentation of dialy-
sis at least 2 times per week for greater than 6 weeks.
Patients who are not on dialysis for more than 6 weeks
with sustained acute renal failure and a GFR of less of
25 by MDRD6 or a direct measurement of GFR would
also qualify for listing. Patients with sustained acute
renal failure with a combination of the aforementioned
2 factors for at least 6 weeks would be acceptable (eg,
patients with a GFR of less than 25 for 3 weeks followed
by dialysis for 3 weeks). Criteria for the initiation of
dialysis are discussed later. The fourth group consists
of patients with metabolic or other genetic diseases and
documentation from a nephrologist specifying the rea-
son for the kidney transplant. This, for example, would
include patients with hyperoxaluria and polycystic liver
and kidney disease.225 These recommendations ap-
peared appropriate, and the group agreed with them,
recommending that the International Liver Transplan-
tation Society support the proposals. They did recom-
mend that caution should be used if the MDRD equa-
tion is used, given its documented inaccuracy in this
group of patients. These panel recommendations incor-
porate metrics and durations of kidney disease that are
somewhat different than those recommended by the
National Kidney Foundation Disease Outcomes Quality
Initiative, which defines chronic kidney disease as kid-
ney damage for 3 months as defined by structural or
functional abnormalities of the kidneys with or without
decreased GFR as manifested by either pathological
abnormalities of urine, blood, or imaging or by a GFR 
60 mL/minute/1.73 m2 for 3 months. This reflects
the high prevalence and very poor prognosis associated
with hepatorenal syndrome, a common cause of renal
disease in patients with liver failure.
The work group felt that these criteria for liver-kidney
transplantation are similar to the ones produced by the
American Society of Transplantation, American Society
of Transplant Surgeons, American Society of Nephrol-
ogy, and United Network for Organ Sharing Consensus
Conference a year ago and recently published in the
American Journal of Transplantation.70 Some of this
work was based on the University of California Los
Angeles liver-kidney transplant experience, which de-
termined that patients who have been dialyzed for 30
days or less prior to liver transplantation do just as well
as patients receiving a combined liver-kidney trans-
plant.67 The workgroup reviewed the results of a recent
article on kidney biopsy in liver transplant candidates
to determine whether or not this would be useful in
allocating patients to receive a liver transplant alone or
a simultaneous liver-kidney transplant. The procedure
allowed this group to avoid a simultaneous liver-kidney
transplant in two-thirds of the patients who underwent
renal biopsy.94 This is similar to the results presented
in preliminary form from the group at the University of
Washington. This group looked at 34 transplant biop-
sies; 18 were listed for liver transplantation alone, and
10 were listed for simultaneous liver-kidney transplan-
tation.226 Although the work group felt that these data
were interesting, the use of kidney biopsy in this setting
was felt to need further study. The group did not rec-
ommend that biopsy data be used to allocate kidneys at
this time, given the small data set and risks of the
procedure, but it highly recommended that further data
be collected.
The United Network for Organ Sharing committees may
also propose criteria for priority kidney allocation after
liver transplantation in patients still on dialysis. It is clear
that some patients have been given a liver only when they
might have qualified for a liver-kidney transplant. Previ-
ous publications have suggested that patients who do not
recover renal function and who require prolonged hemo-
dialysis after liver transplantation have worse posttrans-
plant survival.71 It was felt by the group that these pa-
tients might be given priority for a kidney after liver
transplantation, but there was no consensus. Other
groups who might qualify for priority listing for kidney
transplantation include certain patients receiving a liver
only who did not initially qualify for a simultaneous liver-
kidney transplant. Patients who had been on dialysis pre–
liver transplant for at least 2 weeks and continued on
dialysis for 6 weeks post-transplant were suggested to
receive priority for kidney transplantation. Finally, pa-
tients who had not been on dialysis pre-transplant but
had renal dysfunction for at least 4 weeks pre-transplant
with documented intrinsic kidney disease pre–liver trans-
plant with a GFR between 30 and 40 would be considered
for a priority kidney transplant if they remained on dial-
ysis for 90 days post–liver transplant. It was proposed
that these patients who fulfill 1 of the aforementioned
requirements could qualify for priority points on the kid-
ney transplant waiting list. The working group felt that
points should be determined on the basis of the average
waiting time per disease specific activity (DSA) with the
intent that these candidates will appear on the match list
just below highly sensitized candidates. The feasibility of
calculating DSA-specific points should be explored with
the United Network for Organ Sharing IT Committee. It
TABLE 5. Criteria for Simultaneous Liver-Kidney
Transplantation
End-stage renal disease and dialysis
No dialysis but a glomerular filtration rate  30 mL/
minute and proteinuria  3 g/day with a 24-hour
urine protein/creatinine ratio  3
Acute kidney injury and a requirement for dialysis at
least 2 times per week for more than 6 weeks
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was recognized that the impact of these recommendations
may change in the setting of the new proposed kidney
allocation system based on life years after transplant
gained.227 It was felt that the International Liver Trans-
plantation Society should support the aforementioned
priorities for kidney transplantation in liver allograft re-
cipients. Finally, it was felt that all efforts should be made
to encourage living kidney donation.
Every attempt should be made to improve the pa-
tient’s renal function prior to transplantation, partic-
ularly given the preliminary results of using terlipres-
sin to improve posttransplant outcome.73 It was felt
that the prophylactic measures that are most impor-
tant are the use of terlipressin (not yet approved in
the United States), transjugular intrahepatic porto-
systemic shunt, albumin, and midodrine. The group
also discussed the marked importance of adequate
spontaneous bacterial peritonitis prophylaxis, vol-
ume management, and avoidance of nephrotoxins in
all patients waiting liver transplantation to prevent
deterioration of renal function. A precautionary word
was mentioned regarding the impact of treatment on
allocation by MELD. If the patient’s renal function
improves with the aforementioned measures, the
MELD score may actually decrease, and this would
prolong the waiting time for receiving a liver trans-
plant. There was no consensus on changing the
MELD score for those who respond to treatment strat-
egies at this point, but it was felt that this required
further discussion. The group felt that treatment for
liver-related kidney disease should be started for he-
patorenal syndrome when the creatinine level is
greater than 2 mg/dL. It was clear that further stud-
ies are needed to determine exactly when to start
treatment and what effect this would have on the
waiting time for liver transplantation. It was felt that
the timing of dialysis and ultrafiltration is still quite
center-specific, being determined by a center’s expe-
rience with ease of operative management. The timing
and selection criteria for this treatment need to be
studied. Potential criteria discussed by the group in-
cluded a creatinine level greater than 2 mg/dL, mas-
sive ascites, severe oliguria, severe hyponatremia,
and marginal potassium levels. The group did not
arrive at a consensus concerning when to use intra-
operative renal replacement therapy. Overall, the
group supported aggressive treatment of hepatorenal
syndrome and all forms of kidney dysfunction by what-
ever means a center finds appropriate. This should be
accomplished by improvements in the pretransplant kid-
ney function to improve the posttransplant outcome.
There are not enough data yet to recommend one form of
hepatorenal syndrome treatment, although there are
more patients currently reported to have received vaso-
constrictor therapy.
Recommendations for the Management of
Immunosuppression in Patients with
Preoperative and Postoperative Renal
Dysfunction
Florence Wong, Michael Charlton, and William Wall
The group felt strongly that more randomized con-
trolled trials are needed to determine optimal strategies
for posttransplant renal preservation. Given the impact
of posttransplant renal dysfunction on important out-
comes, it was felt that a low threshold should be used
for employing renal-sparing immunosuppressive proto-
cols. The available data presented and discussed were
synthesized into the following recommendations re-
garding the management of immunosuppression in the
liver transplant recipient with renal dysfunction. Pa-
tients with pretransplant renal dysfunction, defined
minimally as a glomerular filtration rate (GFR)  60
mL/minute, should be considered for a posttransplant
renal-sparing immunosuppressive protocol. Based on
the interpretation of the available data from published
clinical trials reviewed by the group, renal-sparing im-
munosuppression protocols might include the follow-
ing:
1. Induction with interleukin 2 receptor antibodies (ba-
siliximab or daclizumab) or antithymocyte globulin.
2. Mycophenolate mofetil from day 0 and, if needed, as
maintenance.
3. Induction and maintenance of corticosteroids (ta-
pering over 3-6 months).
4. Delay of tacrolimus dosing for 5 to 7 days, with
target 12-hour trough levels of 4 to 6 ng/mL.
RECOMMENDATIONS FOR THE
MANAGEMENT OF IMMUNOSUPPRESSION IN
PATIENTS WITH POSTOPERATIVE RENAL
DYSFUNCTION
Because of the high incidence and prevalence of post-
transplant renal insufficiency, the group felt that renal
function should be measured at regular intervals post-
transplantation. If GFR is 60 mL/minute or if there is
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a 20% reduction in GFR, the evaluation and manage-
ment of renal dysfunction described in a preceding sec-
tion of this report (Evaluation and Pharmacotherapy of
Calcineurin Inhibitor Toxicity) should be initiated.
Once calcineurin inhibitor nephrotoxicity has been di-
agnosed, the consensus recommendation is to reduce
tacrolimus or cyclosporine dosing, regardless of trough
levels at the time of onset of renal dysfunction. The
optimal schedule for dose reduction of tacrolimus/cy-
closporine is not known. However, initial dose reduc-
tions of approximately 30% appear safe in the context of
close biochemical follow-up. Further dose reductions
(0.5-1 mg/dose for tacrolimus and 25-50 mg/dose for
cyclosporine) until the GFR stabilizes or improves or
until doses of 0.5 to 1 mg (tacrolimus) or 25 to 50 mg
(cyclosporine) twice daily are achieved can be consid-
ered. For patients on tacrolimus or cyclosporine mono-
therapy who develop evidence of rejection, the addition
of mycophenolate mofetil and/or prednisone may facil-
itate continued calcineurin inhibitor dose reduction.
The role, if any, of sirolimus in renal preservation strat-
egies is unclear.
Concomitant medical conditions that may contribute
to or exacerbate renal dysfunction should be aggres-
sively managed (eg, dehydration and hypertension). As
always, drug-drug interactions should be considered.
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